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Abstract
Spirometry is the most widely used lung function test in the world. It is fundamental in
diagnostic and functional evaluation of various pulmonary diseases. In the studies
described in this thesis, the spirometric assessment of reversibility of bronchial
obstruction, its determinants, and variation features are described in a general population
sample from Helsinki, Finland. This study is a part of the FinEsS study, which is a
collaborative study of clinical epidemiology of respiratory health between Finland (Fin),
Estonia (Es), and Sweden (S).
Asthma and chronic obstructive pulmonary disease (COPD) constitute the two major
obstructive airways diseases. The prevalence of asthma has increased, with around 6% of
the population in Helsinki reporting physician-diagnosed asthma. The main cause of
COPD is smoking with changes in smoking habits in the population affecting its
prevalence with a delay. Whereas airway obstruction in asthma is by definition reversible,
COPD is characterized by fixed obstruction. Cough and sputum production, the first
symptoms of COPD, are often misinterpreted for “smokers cough” and not recognized as
first signs of a chronic illness. Therefore COPD is widely underdiagnosed. More extensive
use of spirometry in primary care is advocated to focus smoking cessation interventions on
populations at risk. The use of forced expiratory volume in six seconds (FEV6) instead of
forced vital capacity (FVC) has been suggested to enable office spirometry to be used in
earlier detection of airflow limitation.
Despite being a widely accepted standard method of assessment of lung function, the
methodology and interpretation of spirometry are constantly developing. In 2005, the
ATS/ERS Task Force issued a joint statement which endorsed the 12% and 200 ml
thresholds for significant change in forced expiratory volume in one second (FEV1) or
FVC during bronchodilation testing, but included the notion that in cases where only FVC
improves it should be verified that this is not caused by a longer exhalation time in post-
bronchodilator spirometry. This elicited new interest in the assessment of forced
expiratory time (FET), a spirometric variable not usually reported or used in assessment.
In this population sample, we examined FET and found it to be on average 10.7 (SD
4.3)  s  and  to  increase  with  ageing  and  airflow limitation  in  spirometry.  The  intrasession
repeatability of FET was the poorest of the spirometric variables assessed. Based on the
intrasession repeatability, a limit for significant change of 3 s was suggested for FET
during bronchodilation testing. FEV6 was  found  to  perform  equally  well  as  FVC  in  the
population and in a subgroup of subjects with airways obstruction.
In the bronchodilation test, decreases were frequently observed in FEV1 and
particularly in FVC. The limit of significant increase based on the 95th percentile  of  the
population sample was 9% for FEV1 and 6% for FEV6 and FVC; these are slightly lower
than the current limits for single bronchodilation tests (ATS/ERS guidelines). FEV6 was
proven as a valid alternative to FVC also in the bronchodilation test and would remove the
need to control duration of exhalation during the spirometric bronchodilation test.
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ACCP American College of Chest Physicians
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1 Introduction
Flow-volume spirometry is a well-established method used in everyday clinical practice to
assess ventilatory function in both health and disease. The methodology is continuously
under development to better take into consideration accumulating evidence from ongoing
research. Since spirometry is widely used in research, the methodology should be the same
in different international centers. The most recent standard on spirometry issued in 2005
jointly by the American Thoracic Society (ATS) and European Respiratory Society (ERS)
brought small changes and harmonization to the existing methodology (Miller et al.,
2005a, 2005b; Pellegrino et al., 2005). In recent years, office spirometry by primary care
providers has been debated, as a means of earlier detection of chronic obstructive
pulmonary disease (COPD) (Harf, 1992; Ferguson et al., 2000; Enright, 2006a, 2008). In
this context, forced expiratory volume in six seconds (FEV6) has been suggested to replace
forced vital capacity (FVC) in assessment of pulmonary function (Ferguson et al., 2000;
Vandevoorde et al., 2005a, 2006, 2008; Pedersen, 2006; Lamprecht et al., 2007).
Accumulated information on FEV6 is centered on patient samples from pulmonary
function laboratories and less is known about the relationship between FVC, FEV6, and
forced expiratory time (FET) in the general population (Swanney et al., 2000, 2004; Demir
et al., 2005; Vandevoorde et al., 2005a, 2006, 2008; Gleeson et al., 2006; Hansen et al.,
2006a; Melbye et al., 2006; Lamprecht et al., 2007; Bellia et al., 2008).
The prevalence of obstructive airways diseases (OAD), asthma, and COPD is changing
– due to changes in atopic tendency, living standards, and smoking habits. Internationally,
a consensus is lacking on what defines COPD, but generally the existing definitions center
on the ratio of forced expiratory volume in one second (FEV1)  and  FVC.  The  Global
Initiative for Chronic Obstructive Lung Disease (GOLD) and the ATS/ERS consensus
statements  advocate  the  use  of  postbronchodilator  fixed  ratio  and  a  limit  of  70%  to
indicate disease (Global Initiative for Chronic Obstructive Lung Disease; Celli et al.,
2004; Rabe et al., 2007). The use of a fixed limit of FEV1/FVC has been criticized and
limits based on applicable reference values suggested instead (Aggarwal et al., 2006;
Roberts et al., 2006; Hansen et al., 2007; Townsend, 2007). This has also been
recommended in the standards for interpretation of spirometry by the ATS and recently
also the joint ATS/ERS Task Force in 2005 (ATS, 1991; Pellegrino et al., 2005).
The FinEsS study is a collaborative study of clinical epidemiology of respiratory
health between Finland (Fin), Estonia (Es), and Sweden (S). This part of the FinEsS
Helsinki study is based on a random general population sample of adults from Helsinki,
Finland. All participating subjects underwent flow-volume spirometry with
bronchodilation testing. Detailed data were collected to assess variations in FEV1, FVC,
FEV6, and FET during spirometry.
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2 Review of the literature
2.1 Flow-volume spirometry as a lung function measurement
Spirometry has been defined as “a physiological test that measures how an individual
inhales or exhales volumes of air as a function of time” (Miller et al., 2005b). It is used to
assess pulmonary function in the diagnosis of respiratory disease, in occupational and
functional capacity, and in the follow-up of various respiratory diseases. Like blood
pressure measurement in hypertension, it is a fundamental tool in the assessment of lung
function, especially in obstructive airways diseases (OADs) such as asthma and COPD.
All measurements of lung function should be related to reference values that are
representative of the population under investigation (ATS, 1995). In Finland, spirometry
reference values developed by Viljanen and coworkers (1982) from an occupational health
cohort of subjects aged 18-65 years are used, but new reference values with a wider age
range are under way.
2.1.1 Measured variables in flow-volume spirometry
The most important variables from flow-volume spirometry are forced vital capacity
(FVC) and forced expiratory volume in one second (FEV1). FVC is the volume delivered
during  an  expiration  made  as  forcefully  and  completely  as  possible,  starting  from  full
inspiration. FEVt is the maximal volume exhaled by time t seconds (timed from the time
zero defined by back-extrapolation) of a forced expiration from a position of full
inspiration, expressed in liters at body temperature and pressure saturated (BTPS)
conditions (Miller et al., 2005b; Pellegrino et al., 2005). A model maximum expiratory
flow-volume (MEFV) curve is displayed in Figure 1.
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Figure 1 Maximum expiratory flow-volume curve showing the main variables. For
abbreviations, see pages 7-8 (adapted from Sovijärvi et al.,2006).
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Other flow values can also be recorded and used in the assessment. Peak expiratory
flow (PEF) is the maximum expiratory flow achieved from a maximum forced expiration
starting without hesitation from the point of maximal lung inflation, expressed in l/s. The
mean forced expiratory flow between 25% and 75% of the FVC (FEF25-75%) is also
known as the maximum mid-expiratory flow (MMEF). Instantaneous forced expiratory
flow values at 25%, 50%, and 75% of expired FVC are also being reported (FEF25,
FEF50, FEF75), and are of increasing interest in diagnostic evaluation. In the European
literature, these values are referred to as maximal instantaneous forced expiratory flow
where x% of FVC remains to be expired or MEFx (MEF75, MEF50, MEF25), and hence,
MEF75 corresponds to FEF25.
Slow or relaxed vital capacity is measured as a separate maneuver before the forced
expiratory maneuvers. The slow vital capacity (VC) may be larger than FVC, especially in
subjects with airflow limitation (Brusasco et al., 1997). Corresponding indices can be
measured from inspiratory spirometry, but usually only forced inspiratory vital capacity
(FIVC), forced inspiratory volume in one second (FIV1), and peak inspiratory flow (PIF)
are reported.
In 1987, Glindmeyer and coworkers suggested from a purely mathematical model that
an end-of-test criterion based on a fixed duration of the FVC maneuver could be applied.
Using the standard waveforms presented by Hankinson and Gardner in 1982, which have
later been adopted into the ATS 1987 and 1994 standards (ATS, 1987; ATS, 1995), they
found that 6.64 s was sufficient to obtain 99% of FVC for spirograms with FEV1/FVC as
low as 50% (Glindmeyer et al., 1987).
FVC is known to be dependent on expiratory time, particularly in obstructive patients
and in the elderly (Glindmeyer et al., 1987; Swanney et al., 2000). To overcome problems
with FVC, forced expiratory volume in six seconds (FEV6) has been suggested to be used
in lieu of FVC, especially in primary care office spirometry (Ferguson et al., 2000; Derom
et al., 2008). FEV6 is easier for patients to complete and its measurement requires less
expensive flow-sensors (Ferguson et al., 2000; Swanney et al., 2000). The use of FEV6
necessitates applicable reference equations, which have already been calculated at least in
the United States (Hankinson et al., 1999, 2003), in New Zealand (Marsh et al., 2006), in
elderly South-European adults (Garcia-Rio et al., 2004), and in Brazil (Pereira et al.,
2007). Although FVC measurements are recognized to be dependent on total expiratory
time, limited data exist on the difference between FVC and FEV6 in healthy adults or in
population samples (Hankinson et al., 2003).
In addition to FEV6, FVC6 is sometimes used. FVC6 refers to measurement of FEV6
using a dry-wedge spirometer, still used in field studies but rarely in office spirometry or
hospital-based pulmonary function laboratories. In these spirometers, air cooling during
the maneuver results in a small dip or reduction of exhaled air volume at the end of
MEFV, which means that FVC6< FEV6, although the difference is usually very small
(about 0.050 liters) (Hankinson et al., 2003; Akpinar-Elci et al., 2006; Lamprecht et al.,
2007).
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Forced expiratory time (FET) has not been traditionally considered a flow-volume
spirometry variable, but rather a quality measure signifying satisfactory duration of
exhalation. Longer FET during a single pulmonary function testing session has been
associated with better spirometric performance in terms of FEV1+FVC (Tsai et al., 2006).
No reference values exist for FET, and it is not usually reported or used in diagnostic
evaluation.
FET has originally been investigated as a clinical sign in diseases with chronic
obstruction (Rosenblatt & Stein, 1962; Godfrey et al., 1969, 1970; Kern & Patel, 1991,
1994; Holleman et al., 1993; Schapira et al., 1993; Straus et al., 2002), particularly small
airways obstruction (Macdonald et al., 1975). In these studies, auscultated FET was
usually measured with a stethoscope above the trachea. A normal duration of auscultated
forced expiration has been considered to be less than 4 s (Rosenblatt & Stein, 1962;
Campbell, 1969), but in some older normal subjects airflow can persist for long periods,
although the rates are too low to be detected clinically (Leith & Mead, 1967). Auscultated
FET is shorter than spirometric FET since flow at a certain point falls below a limit
detectable by auscultation (Lal et al., 1964). The diagnostic accuracy of FET
measurements in clinical use has been questioned (Badgett & Tanaka, 1994). In subjects
without airflow limitation or restriction in baseline spirometry evaluated for symptoms
suggestive of asthma, spirometric FET has been found to generally be under 6 s and
shorter in subjects that demonstrated bronchial hyperresponsiveness (Goldstein et al.,
2002). However, most studies reporting FET have excluded subjects with FET<6 s, and in
these studies mean FET has been around 8-11 s (Hankinson et al., 1977; ATS, 1979;
Vandevoorde et al., 2005a, 2006; Gleeson et al., 2006; Jensen et al., 2006).
2.1.2 Determinants of lung function
In childhood and early adulthood, the level of attainable lung function has been shown to
be determined by race, genetic predisposition, height, severe or recurrent infections in
childhood, respiratory symptoms and disease in childhood, and inhalational exposures,
especially to environmental tobacco smoke and air pollution (Lewitter et al., 1984;
Woolcock et al., 1984; Lebowitz et al., 1987; Shaheen et al., 1995; Gauderman et al.,
2000, 2004, 2007; Sandström & Brunekreef, 2007). Young age at smoking initiation is a
risk for both accelerated decline of lung function and failure to reach target growth (Tager
et al., 1985, 1988; Lebowitz et al., 1987; Jaakkola et al., 1991).
Of the anthropometric variables, lung function has generally been considered to be a
function of race, gender, age, and height, and these variables have most often been
included in the reference equations for adults (Morris et al., 1971, 1988; Crapo et al.,
1981; Viljanen et al., 1982; Knudson et al., 1983; Quanjer et al., 1983; Miller et al, 1986;
Paoletti et al., 1986; Roca et al., 1986, 1988; Hankinson et al., 2003; Marsh et al., 2006;
Perez-Padilla et al., 2007).
The strongest determinant of accelerated decrease in FEV1 is smoking, with a
population attributable risk (PAR) for COPD of around 80% (Tashkin et al., 1984, 1994;
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Camilli et al., 1987; Peat et al., 1990; Kerstjens et al., 1997; Wilson et al., 2005; Viegi et
al., 2007). Women might be more susceptible to the adverse effects of smoking and
environmental tobacco smoke (ETS) (Chen et al., 1991; Prescott et al., 1997; Langhammer
et al., 2003) or gender might influence disease detection and management (Dales et al.,
2006). In addition, inhalation of various other noxious substances, especially vapors,
dusts, gases, and fumes (VDGF) has been reported to increase the risk of chronic airflow
limitation (van der Lende et al., 1981; Becklake, 1989; Bakke et al., 1991). In a recent
Nordic report, Johannessen and coworkers (2005) estimated in a population sample the
PAR of smoking-related COPD to be 68%, while occupational exposure to VDGF
accounted for about 6% of cases. Long-term exposure to particulate air pollution, namely
PM10 particles, has been associated with loss of attainable lung function in children and
higher prevalence of airflow limitation and respiratory symptoms in adults (Tashkin et al.,
1994; Gauderman et al., 2000, 2004, 2007; Pénard-Morand et al., 2005; Rojas-Martinez et
al., 2007).
Moreover, excessive body weight has been described to play a significant role (Chinn
et al., 1996), with weight gain influencing decrements in FEV1 as much as cigarette
smoking in subjects aged under 35 years (Morgan & Reger, 2000). Particularly abdominal
adiposity seems to play a role (Ochs-Balcom et al., 2006). Physical activity has been
demonstrated to slow down the decline of lung function (Pelkonen et al., 2003).
Aging is a problematic aspect in many lung function measures since reference values
are often formed from measurements of working age populations and extrapolation of
these values to older age cohorts systematically introduces a representation bias to the
analysis (Burrows et al., 1986; Janssens et al., 1999; Hardie et al., 2002). However,
studying healthy elderly never-smokers may not completely eliminate the representation
bias since significant selection will have occurred - those who are “healthy” in the
octagenaries  probably  also  represent  some  genetic  predisposition  to  different  body
composition among the various acquired traits (Janssens et al., 1999). FEV1 has also been
shown to be a prognostic measure, with lower FEV1 related  to  increased  morbidity  and
mortality in the population (Hansen et al., 1999; Knuiman et al., 1999; Anthonisen, 2000;
Pelkonen et al., 2000, 2006; Schünemann et al., 2000; Thomason & Strachan, 2000;
Mannino et al., 2003, 2006a, 2006b).
2.1.3 Pathological changes in flow-volume spirometry
The pathological changes in flow-volume spirometry can be classified broadly into
obstructive, restrictive, and combined (mixed) ventilatory abnormalities. Obstructive
airways  diseases,  mainly  asthma  and  COPD,  constitute  a  major  portion  of  those
pulmonary diseases that can be diagnosed with routine flow-volume spirometry.
Asthma is an inflammatory condition of the airways characterized by eosinophilic
inflammation that leads to smooth muscle contractility, bronchial hyperresponsiveness,
and variable airways obstruction (Global Initiative for Asthma; Bateman et al., 2008).
Ongoing eosinophilic inflammation can be detected by exhaled nitric oxide (NO) and
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inflammatory substances (e.g. eosinophilic cationic protein) in the sputum and exhaled
breath  condensate  of  patients  with  asthma (Kharitonov & Barnes,  2001;  Horvarth  et  al.,
2005; Birrell et al., 2006; Taylor et al., 2006; Bateman et al., 2008). The clinical picture is
characterized by recurrent episodes of breathlessness and wheezing, particularly at night.
Airways obstruction is reversible in response to bronchodilating medication or
spontaneously over time (Bateman et al., 2008).
Chronic obstructive pulmonary disease is caused by inhalation of noxious substances,
most commonly tobacco smoke (Global Initiative for Chronic Obstructive Pulmonary
Disease; Rabe et al., 2007; Viegi et al., 2007). The inflammation in COPD is mainly
neutrophilic and the disease is characterized by a triad of chronic productive cough
(chronic bronchitis), emphysema, and airflow limitation. At the early stages of the disease,
changes can be seen in small airways but as the disease progresses also larger airways are
affected. Disease phenotypes differ with some subjects mainly affected with emphysema
whereas others presenting mainly airways obstruction (Global Initiative for Chronic
Obstructive Pulmonary Disease). The risk of developing COPD increases with increasing
smoking pack-years and ageing. Of older subjects with a smoking history of over 40 pack-
years, more than 50% were found to have chronic obstruction in Northern Finland
(Kotaniemi et al., 2005).
Obstruction
An  obstructive  ventilatory  defect  is  defined  as  a  reduction  of  maximal  airflow  from  the
lung disproportionate to the maximal volume (i.e. VC) that can be displaced from the lung
(Pellegrino et al., 2005). It implies airway narrowing during exhalation and is
characterized by a FEV1/VC ratio below the 5th percentile of the predicted value.
However, at the early stages of airflow limitation, changes are seen in the terminal portion
of the spirogram that reflects changes in the small airways. A schematic illustration of the
spirograms associated with typical obstructive ventilatory defects are shown in Figure 2.
The degree of obstruction is graded based on FEV1 (Pellegrino et al., 2005).
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Figure 2 Flow-volume spirometry curve displaying characteristic obstructive ventilatory defect
shown with grading from mild to severe obstructive ventilatory dysfunction (adapted
from Sovijärvi et al.,2006).
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A fixed ratio of FEV1/FVC below 70% for the diagnosis of airflow limitation
signifying COPD has been advocated by the international guidelines, namely the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (Global Initiative for
Chronic Obstructive Pulmonary Disease; Rabe et al., 2007). The use of a fixed ratio limit
has been criticized for underdiagnosing the young and overdiagnosing the elderly (Hardie
et al., 2002; Hansen et al., 2006b, 2007; Roberts et al., 2006). Values relative to
representative reference values taking into consideration differences in race, gender, age
and height are suggested with the applicable lower limit of normal (LLN) used to define
abnormal (Pellegrino et al., 2005). The degree of over- and underdiagnosis with the fixed
ratio limit is dependent on the reference values used.
FET can be measured by auscultation of the chest wall or trachea, or from spirometry.
FET is prolonged in subjects with airway obstruction (Hankinson, 1977; ATS, 1979;
Vandevoorde et al., 2005a). Auscultated FET had good sensitivity (92%) but poor
specificity (43%) for detection of large airways obstruction (Kern & Patel, 1991).
Auscultated FET was rejected early on as a screening test for small airways obstruction on
the grounds that its intrasubject variability exceeded that of the spirometrically determined
FEF25-75% (Macdonald et al., 1975). In their retrospective patient sample, Vandevoorde
and coworkers (2005a) reported that spirometric FET was 8.8 (SD 2.6) s in men without
airway obstruction and 10.9 (3.7) s in men with airway obstruction. In women the
corresponding values were 8.1 (2.1) s and 9.8 (3.1) s, respectively. Unfortunately, in their
study subjects with FET<6 s had been excluded before analysis, because shorter
exhalations were considered technically unacceptable (Vandevoorde et al., 2005a).
The sensitivity and specificity of the FEV1/FEV6 ratio in identifying cases with airflow
limitation have been evaluated in various settings and in many cases with varying
exclusion criteria. When assessing studies on patient populations, the essential factors to
be taken into consideration include the prevalence of disease, the severity of disease
found, and the impact of physiologic changes related to increasing age.
FEV1/FEV6<LLN has been reported to have 76.7-97% sensitivity and 47.0-98.2%
specificity in the diagnosis of obstruction compared with the gold standard of
FEV1/FVC<LLN (Swanney et al., 2000; Vandevoorde et al., 2005a, 2006; Gleeson et al.,
2006; Hansen et al., 2006a). The widely differing sensitivity and specificity values have
been attributed to differences in the prevalence of obstruction, from 21% (Hansen et al.,
2006a) to over 50% (Swanney et al., 2000), the degree of obstruction, the definition of
”abnormal”, and patient selection. A correction of ±5% and LLN±2% for the day-to-day
variability of spirometry, improved the specificity of the measurement to 97.4% (Swanney
et al., 2000). Besides a high prevalence of obstruction in that study, many of them were
severe in degree. On the other hand, Gleeson and coworkers (2006) defined obstruction as
FEV1/FVC or FEV1/FEV6?100% predicted, resulting in a greater number of borderline
cases being labelled as obstructive and a greatly reduced specificity (47%). Most
discordant cases between FEV1/FVC and FEV1/FEV6 have  had  values  close  to  the  LLN
(Vandevoorde et al., 2005a; Hansen et al., 2006a; Vandevoorde & Swanney, 2006). In
most studies, FET<6 s has been an exclusion criterion, which has resulted in omission of
5.4% (Vandevoorde et al., 2005a) to 37% (Gleeson et al., 2006) of subjects and produced
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sample selection. The exclusion of FET<6 s spirometries from analysis will reduce the
number  of  normal  and  restricted  ventilatory  defects,  hence  causing  oversampling  of  the
obstructive ventilatory defects. It reflects the high quality of spirometric measurements to
be expected from tertiary care pulmonary function laboratories and should be taken into
consideration when assessing the usability of FEV6 and FEV1/FEV6 in office spirometry
and screening. In occupational screening spirometries, a sensitivity of 92% and a
specificity of 98% have been reported, with an acceptable rate of misclassification
compared with FEV1/FVC (Akpinar-Elci et al., 2006).
Because of the limited availability of reference values for FEV6, especially in Europe,
and the widespread use of fixed ratio criteria in the diagnosis of COPD, comparable values
have been assessed for FEV1/FEV6. Using the same cut-off level of 70%, only 86%
sensitivity  was  reported  for  FEV1/FEV6 (Demir et al., 2005). The fixed cut-off of
FEV1/FEV6<73% by contrast, is comparable with FEV1/FVC<70%, with 94.4%
sensitivity and 93.3% specificity in a large retrospective patient sample of 11,676 adults
with a prevalence of obstruction of 45.9% (Vandevoorde et al., 2006). This same fixed
cut-off level has been found applicable in elderly subjects in Norway (Melbye et al.,
2006), where the difference between FEV1/FVC and FEV1/FEV6 was  shown to  increase
with advancing age, smoking, and decreasing FEV1/FVC ratio  (Melbye  et  al.,  2006).  In
the population study by Hansen and coworkers (2006a), substituting FEV6 for FVC
reduced the sensitivity of spirometry to detect airway obstruction, especially in older
individuals and those with minor obstruction. FEV1/FEV6 values have been found to be
useful in following the course of OAD in smokers and for screening smokers for the
presence of airway obstruction in the Lung Health Study (Enright et al., 2002). Other
indices,  e.g.  FEV3/FVC, 1-FEV3/FVC, and FEF25-75/FVC, have been evaluated as
measures of bronchodilation, but have yet to demonstrate utility (Hansen et al., 2006b).
With accumulated information on the usability of FEV1/FEV6 in detecting obstruction,
the gold standard of obstruction has been debated (Vandevoorde et al., 2005b, 2006;
Vandevoorde  &  Swanney,  2006).  The  reliable  measurement  of  FVC  is  sometimes
challenging. As long as FVC is used as the gold standard, FEV6 cannot outperform FVC
in the spirometric assessment of pulmonary function abnormalities (Vandevoorde et al.,
2006). Additionally, most discordant cases are located at the borderline between normal
and abnormal. Swanney and coworkers (2000) attempted to compensate for this with their
variability correction; however, proper reference values should be developed and used
with no additional corrections being necessary (Lamprecht et al., 2007).
Subjects  with  FEV1/FVC<LLN and FEV1>LLN are  considered  in  the  GOLD criteria
to have stage I COPD (Rabe et al., 2007), but this definition has been questioned and these
subjects considered normal variants (Vandevoorde & Swanney, 2006). FEV1/FVC
physiologically diminishes with aging, resulting in potential overdiagnosis (Hardie et al.,
2002; Hansen et al., 2006b; Roberts et al., 2006; Medbø & Melbye, 2007). Therefore a
limit of 65% has been suggested in subjects aged 70 years or over (Medbø & Melbye,
2007). However, in the elderly, FEV1/FVC<70% and FEV1/FVC?LLN have been
associated with increased mortality (Mannino & Davis, 2006; Mannino et al., 2006, 2007).
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FEV1 has also been shown to be a measure of overall increased mortality and morbidity
(Hansen et al., 1999; Knuisman et al., 1999; Schünemann et al., 2000).
In summary, with the use of appropriate reference equations, FEV1/FEV6 has been
assessed to be as good as FEV1/FVC in predicting obstruction (Enright, 2006b; Pedersen,
2006; Lamprecht et al., 2007).
Restriction
A restrictive ventilatory defect is defined as being ”characterized by a reduction in TLC
below the 5th percentile of the predicted value and a normal FEV1/VC” (Pellegrino et al.,
2005). Restrictive abnormality can be suspected based on flow-volume spirometry
showing reduced VC, high FEV1/VC (>85-90%), and a flow-volume curve showing a
convex pattern. Reduced VC in itself does not prove a restrictive ventilatory defect, being
associated with low TLC in no more than half the cases (Aaron et al., 1999; Glady et al.,
2003). A schematic illustration of the spirometry curves displaying typical restrictive
ventilatory defects are shown in Figure 3. Based on the 2005 ATS/ERS standard, the
degree of restriction is also graded based on FEV1 (Pellegrino et al., 2005).
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Figure 3 Flow-volume spirometry curve showing characteristic restrictive ventilatory defect
with grading from mild to severe restrictive dysfunction (adapted from Sovijärvi et
al., 2006).
FEV6 is lower than FVC, especially in individuals with airflow limitation. Demir and
coworkers (2005) found in their study of 5,114 patients four subjects with a difference
between FVC and FEV6 that was greater than one liter. Swanney and coworkers (2004)
compared three spirometric algorithms against the gold standard of body pletysmographic
TLC in the diagnosis of restriction and found that all of the evaluated algorithms had
?99% accuracy in predicting normal or increased TLC, but that in the prediction of
restriction the predictive accuracy was around 50%. However, FEV6 performed equally
well  as FVC, and the authors concluded that FEV6 could be used in lieu of FVC for the
spirometric detection of restriction, given that FVC also performs very poorly (Swanney et
al., 2004). Glady and coworkers (2003) reported no difference between FVC and slow VC
in the prediction of restriction.
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Vandevoorde and coworkers (2005a) have first reported in 2005 on a large
retrospective patient sample of 11,676 subjects with FET>6 s, with spirometric restriction
defined as FVC<LLN in the presence of a normal FEV1/FVC ratio. Substituting FEV6 for
FVC reduced the sensitivity of detection of restriction to 83.2% and specificity to 99.6%.
The prevalence of restrictive pattern (with FVC) was 15.7% (Vandevoorde et al., 2005a).
Then, in 2006, the same researchers described based on another large routine pulmonary
function test laboratory material the utility of FEV6 in the diagnosis of restriction
combined with FVC (Vandevoorde et al., 2006). FEV6 in combination with FVC had an
improved sensitivity of 95.9% and specificity of 98.6% for the diagnosis of restriction,
while the prevalence of spirometric restriction (defined as FVC<LLN) was 14.9%
(Vandevoorde et al., 2006).
More recently, Vandevoorde and coworkers (2008) have investigated the ability of
FEV6 and FVC from flow-volume spirometry to predict reduced total lung capacity
(restriction) in a patient sample of 12,693 subjects. Obstruction was defined as FEV1/FVC
or FEV1/FEV6<LLN. TLC was measured by body plethysmograph and used as the
reference standard for restriction. Both FVC and FEV6 had low positive and high negative
predictive values. In nonobstructive subjects, they found that restriction could be
positively predicted if FVC or FEV6 was <55% for males or <40% for females, but that in
obstructive patients spirometry could not reliably diagnose a concomitant restrictive
defect. However, spirometry can rule out restriction in patients with FVC or FEV6 >85%
predicted in men and >70% predicted in women (Vandevoorde et al., 2008).
In conclusion, FEV6 has been shown to have lower sensitivity in the detection of
restrictive than obstructive disorders, but other flow-volume spirometry variables, namely
FVC and VC, perform equally poorly (Pedersen, 2006; Vandevoorde et al., 2008).
Mixed abnormalities
A  mixed  ventilatory  defect  is  characterized  by  the  coexistence  of  obstruction  and
restriction, and is defined physiologically when both FEV1/VC and TLC are below the 5th
percentiles of their relevant predicted values (Pellegrino et al., 2005). During the course of
obstructive airways disease, narrowing of the airway lumen causes air trapping, which
results in dynamic hyperinflation and the development of a dynamic restriction (Pellegrino
& Brusasco, 1997; O’Donnell et al., 2001; Calverley & Koulouris, 2005).
2.2 Standardization of spirometry
The standardization of spirometry dates back to the 1970s, when both in the United States
and in Europe technical development necessitated local agreements on methods to be
applied. On both continents, the initial drive to standardization of methods came from
occupational interests since legislation was enacted that required medical surveillance of
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workers exposed to respiratory hazards (Theodos et al., 1975). Epidemiologic research
increased markedly, requiring comparability of data and diagnostic criteria.
2.2.1 The American Thoracic Society
In  the  United  States,  the  coordination  efforts  were  started  slightly  earlier,  with  the  first
recommendations published in 1975 (Theodos et al., 1975) and the first consensus
statement reached in the Snowbird Workshop on standardization of spirometry held in
1977 (ATS, 1979). Thereafter, the American College of Chest Physicians (ACCP)
published their own recommendations (in 1983), basically endorsing the Snowbird
Workshop results (Zamel et al., 1983).
Standardization work continued on a wider basis driven by both accumulated
experience and the advent of computerized spirometers. An update on methodology was
published in 1987 (ATS, 1987) and a consensus document on reference values and
interpretative principles in 1991 (ATS, 1991). The start-of-test criteria were based on the
back-extrapolation method, with a tighter limit for extrapolated volume (EV) at 5% of
FVC or 0.100 liters, whichever was greater. This was a significant reduction from the
previously accepted upper limit of 10% of FVC (Zamel et al., 1983). The 1987 update also
introduced the current form of end-of-test criteria. An end-expiratory pleateau was
required for at least 2 s, with an exhalation time of at least 6 s or a forced exhalation of
reasonable duration (longer than 15 s was considered not to change clinical judgment) or
when for legitimate clinical reasons the subject cannot or should not continue further
exhalation. The repeatability criteria became more specific with an upper limit of 5% of
the respective volume or 0.100 liters instituted for both FVC and FEV1. The 1979
document was unclear in the interpretation of which volume 5% was to be calculated, and
the new standard resolved this ambiguity. In the 1987 update, the ATS also took a stance
to discourage the elimination of subjects from epidemiological studies on the grounds of
poor reproducibility since this had been demonstrated to result in a population bias (Eisen
et al., 1984, 1985; Kellie et al., 1987). The concept of “best test” defined in terms of
largest sum of FEV1 and FVC was also endorsed.
A separate standard on the interpretation of spirometry was published in 1991. This
document introduced the current bronchodilation test limits of 12% of FVC or FEV1 from
baseline with a concurrent absolute change of 200 ml required (ATS, 1991). Previously,
the Intermountain Thoracic Society had advocated the use of a 15% change in FVC, a
12% change in FEV1, or a 45% change in FEF25-75%, and the ACCP a limit of 15-25%
for all three variables (Morris et al., 1984; ATS, 1991).
Although workshops were held also on dealing with coordination of measurements of
lung volumes, this was not addressed in the published standards. The standardization of
spirometry was updated in 1994 to take into account technical developments, most notably
driven by the rapid development of computers (ATS, 1995). It included a separate
category for monitoring devices, with slightly less stringent measurement quality criteria
applied. Instructions for BTPS corrections were more specific and detailed, with
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accumulated data on the effects of BTPS corrections on results. The acceptability criteria
included EV (<5% FVC and <0.150 liters) and an interim criterion of time-to-PEF<120
ms. The repeatability criteria were changed to equal volume criteria of FVC or FEV1
?0.200 liters, to accommodate the view that relative change values would misclassify
subjects with small lung volumes as having poorly repeatable tests (ATS, 1995).
2.2.2 The European Respiratory Society
In Europe, national recommendations prevailed until 1983, when collaborative work
within the European Community for Coal and Steel (ECCS) coordinated the first standard
(Quanjer et al., 1983). The standardization was driven by needs of occupational health
providers for uniform standards to assess potential work-related hazards to respiratory
health. Soon thereafter, the European Respiratory Society (ERS) participated in the
update, which was then endorsed as an official statement of the ERS (Quanjer et al.,
1993).
In the 1993 ERS standard, the main differences in ATS criteria were in the applied
curve and variable selection criteria. The ERS standard states that the inspiratory vital
capacity (IVC), FVC, FEV1, and PEF be taken from the largest respective value from the
first three technically satisfactory determinations. For IVC, FVC, and FEV1, the chosen
value should not exceed the next highest one by more than 5% or 100 ml, whichever is
greater. The start of the forced expiration is obtained by back-extrapolation. EV should not
exceed 5% of the FVC or 100 ml, whichever is greater. MMEF is taken as the largest
value from the first three technically satisfactory curves provided that the curve has a FVC
that differs less than 5% from the largest FVC. MEFx values are taken from an envelope
of at least three technically statisfactory MEFV curves, which are superimposed from total
lung capacity (TLC). Alternatively, the standard leaves it optional to take the highest value
from a set of three curves provided that the FVC of the chosen curves differs less than 5%
from the largest FVC. The curves should have comparable form, and the PEF values
should differ less than 10% from the largest one (Quanjer et al., 1993). The PEF
repeatability criteria advocated in the ERS 1993 standard are therefore quality criteria to
ensure other flow values are taken from maneuvers with maximum effort.
The ERS 1993 standard also advocates the use of a uniform set of European reference
values based on Quanjer and coworkers (1993), whereas the ATS standard did not take a
stance  on  any  one  set  of  reference  values,  instead  focusing  on  the  representativeness  of
selected reference values at the local level and stressing the need to update reference
values regularly (ATS, 1995). The European reference values are based on a collection of
earlier studies, and their continuing use has recently been debated (Degens & Merget,
2008).
In bronchodilation testing, the ERS 1993 standard recommends the use of absolute and
relative to reference value change in FEV1 and FVC, setting the limit of significant change
at 12% of predicted and 200 ml (Quanjer et al., 1993). Additionally, in adults, an increase
in PEF of 60 l/min after administration of a bronchodilator drug was considered to
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indicate a clinically significant improvement. The use of MMEF or other instantaneous
flows was discouraged.
In 1995, European scientists participated in the ATS updates of standards for
spirometry and single-breath carbon monoxide diffusing capacity of the lung, but no joint
statement was published by the two societies until 2005 (Brusasco et al., 2005). Although
very similar in many aspects, the two major standardization efforts also differed on
significant issues, which have had implications for research and development of
international guidelines on the diagnosis and treatment of various respiratory conditions,
e.g. COPD. The need for harmonization was widely acknowledged already in the mid-
1990s  and  prompted  the  formation  of  joint  task  forces  between  the  ATS  and  ERS  to
develop standards in pulmonary function testing, including spirometry.
2.2.3 ATS/ERS Task Force 2005
Internationally, the slightly differing definitions of the ATS and the ERS were recognized
to need harmonization to foster research. The joint task force was created to tackle issues
of standardization in different lung function measurements – spirometry, diffusion
capacity, and body pletysmography. The outcome of this work was published in 2005 as a
series in the European Respiratory Journal (Miller et al., 2005a, 2005b; Wanger et al.,
2005; MacIntyre et al., 2005; Pellegrino et al., 2005).
The  joint  ATS/ERS  2005  standard  on  spirometry  (Miller  et  al.,  2005b;  Pellegrino  et
al., 2005) followed the previous ATS 1994 standard on most key issues. This was
expected since the ATS standard had been widely adopted in research. The separate
category of monitoring devices was discarded with the intention of producing minimum
criteria to be fulfilled by all devices used in patient studies. Single curve acceptability
criteria included EV being <5% of FVC or 0.150 liters, whichever is greater. On
repeatability criteria, the two largest FVC and FEV1 should be within 0.150 liters,
however, when FVC< 1.0 liter, these values are reduced to 0.100 liters. All other flow
values should be taken from the “best curve”, which is defined as the curve with the
largest sum of FEV1 and FVC. The endorsement of the “best curve” concept clarified the
selection  of  flow  values  and  left  no  room  for  interpretation  in  curve  selection.  For  lung
volume, the largest value of FVC, FIVC, or VC was suggested and especially for the ratio
FEV1/FVC used for the diagnosis of COPD.
FEV6 was included in the new standard and its better repeatability (compared with
FVC) and easier completion were noted, but the statement fell short of recommending its
use. It has been speculated that this could be because European reference values for
general use are still lacking (Laszlo, 2006).
In bronchodilation testing, the task force endorsed the ATS 1994 criteria, namely the
use of change relative to baseline and absolute change, with values exceeding 12% and
200 ml of either FVC or FEV1 considered significant (Pellegrino et al., 2005). However,
the new standard also noted the potential cases where bronchodilation is seen only in FVC
and added the requirement that expiratory time not change if an “isolated volume
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response” is documented. The term “isolated volume response” was used to describe a
situation where only FVC, not FEV1, increases significantly during the bronchodilation
test.
The updated ATS/ERS standards have been adopted in Finland in the national Finnish
guidelines that have also been updated in 2006 (Sovijärvi et al., 2006). A new task force
on pulmonary function testing, implemented by the Forum of International Respiratory
Societies  (FIRS)  has  recently  started  its  work  based  on  the  ATS/ERS  documents
(Brusasco et al., 2005).
2.3 Repeatability of spirometry
The repeatability and variability of spirometry have been extensively investigated during
the 1960s and 1970s (Dawson, 1966; Ashrift et al., 1969; McCarthy et al., 1975; Knudson
et al., 1976a, 1976b; Cochrane et al., 1977; Nickerson et al., 1980), but since the
standardization work had only just started, these studies are not comparable with modern
flow-volume spirometry. The measurements and their selection for interpretation differ
from the current methods. Repeatability studies among patients with OAD are problematic
since variations in spirometry reflect characteristic changes in the disease state in addition
to measurement variability. Additionally, assessment of “normal” in these studies has
usually been self-reported and is not based on medical evaluation. The method of
assessing variability in the studies also varies, with reported percentages not always being
directly comparable.
Besides repeatability of the measurement in itself, factors related to instrumentation,
technicians, timing of previous medication, and any medication wash-out periods used
affect the measurement (Glindmeyer et al., 1982; Demets, 1990; Enright et al., 1995;
Künzli et al., 1995; Chinn et al., 2006).
2.3.1 Intrasession repeatability of spirometry
A flow-volume spirometry measurement consists of three acceptable determinations
fulfilling repeatability criteria as stated above. Intrasession repeatability refers to the
difference between these three determinations.
In healthy adults completing spirometry on multiple occasions, the intrasession
repeatability of FVC and FEV1 in terms of CoV was 2.7% during multiple measurements
in one day and 1.8% during weekly measurements; the corresponding figures for FET
were 11.8% and 13% (Cochrane et al., 1977). In asymptomatic never-smoking Norwegian
men (n=4,989) aged 30-46 years participating in a community survey, the within-subject
standard deviation from three recordings of FEV1 and FVC was on average 102 and 106
ml, respectively, increasing with height and BMI (Humerfelt et al., 1998). Small, but
significant, differences were observed between technicians in within-subject repeatability
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and levels of FEV1 and FVC (Künzli et al., 1995; Humerfelt et al., 1998; Chinn et al.,
2006).
In patients completing routine spirometry, the coefficient of variation has been
reported to be 14.8% for FET and 4.7% for FVC, with longer FET being associated with
better performance in spirometry expressed in terms of FEV1+FVC (Tsai et al., 2006).   In
a population sample, Hankinson & Bang (1991) found both older and younger subjects to
have more difficulty to satisfy ATS acceptability and reproducibility criteria. In addition,
the reproducibility criteria relative to FVC and FEV1 seemed to classify a higher
percentage of subjects with smaller height and lung volume as having a nonreproducible
test (Hankinson & Bang, 1991).
Ninety percent of patients (n=18,000) completing routine flow-volume spirometry in a
pulmonary function laboratory were able to reproduce FEV1 within 120 ml (6.1% of best
FEV1) and FVC within 150 ml (5.3% of best FVC) in a retrospective analysis of patient
records (Enright et al., 2004). Older subjects were able to reproduce repeatable
spirometries as often as younger patients, but shorter patients and subjects with worse
baseline lung function were less able to obtain reproducible maneuvers when expressed as
a percentage difference (Enright et al., 2004).
The  index  of  variability  of  each  timed  volume  (FEVt) from 1 to 12 s in subjects
(n=3,539) participating in screening flow-volume spirometry during an epidemiological
survey was calculated, and the least within-test session variability expressed in terms of
average range was seen for FEV6 and FEV7, both having a mean range of 95 ml (Jensen et
al., 2006). FET under 10 s was an exclusion criterion in the study.
Sourk and Nugent (1983) evaluated 79 patients referred to a pulmonary function test
and randomized 42 subjects to placebo inhalations and 37 to receive metaproterenol 1,500
µg in a blinded study on variability of spirometry. In response to the placebo inhalations,
FVC changed on average 1.3% (SD 6.7%) and had an upper confidence limit of 14.9%.
This corresponds to a mean difference of 25 ml (SD 156 ml) and an upper confidence limit
of 340 ml. Concurrently, FEV1 changed on average 0.97% (SD 5.6%) or 11 ml (83 ml),
with an upper confidence limit of 12.3% or 178 ml. In this heterogeneous patient material,
baseline pulmonary function and clinical factors were reported to have no apparent effect
on placebo responses (Sourk & Nugent, 1983).
2.3.2 Circadian variation
In healthy adults pulmonary function, particularly FEV1,  has  been  shown  to  follow  an
endogenous circadian rhythm with minimum values occurring during the usual sleep
period during night even in subjects maintaining wakefulness (Spengler & Shea, 2000).
On the contrary, FVC remained fairly constant with no circadian variation observed. The
ranges (peak to trough) of mean circadian changes in spirometric variables were 2.0-3.2%
of average values with individual circadian rhythms (within-subjects) generally larger than
the group average changes (between-subjects) (Spengler & Shea, 2000).
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Circadian variation in lung function has been studied in a population sample (n=876)
with measurements between 09:00 and 21:00 and on four occasions at three-year intervals
(Borsboom et al., 1999). Spirometric variables increased from 09:00 until noon, and
decreasing thereafter. Average variation in FVC was 4.8% (200 ml) and in FEV1 2.8% (86
ml) adjusted to average level. In healthy non-asthmatic volunteers, the coefficient of
variation was lowest intrasession (1.5% for FEV1 and 3.1% FVC) and highest over 12 h
(3.2% for FEV1 and 4.1% for FVC) (Randell et al., 1999). In both of these studies, the
average diurnal variation was found to be large in relation to longitudinal change, but the
authors suggested that longitudinally comparable measurements should be collected after
11:00 to minimize the confounding effect of diurnal changes on judgement of longitudinal
changes (Borsboom et al., 1999; Randell et al., 1999). Similar results were earlier reported
for 15 subjects (including 5 normal controls) measured five times over two days, with a
diurnal  variation  in  FEV1 found and the highest flows being recorded at midday; the
difference was not, however, significant (Hruby & Butler, 1975).
Nineteen stable asthmatics and ten normal controls performed portable spirometry
every two hours during the day (from 8:00 until 22:00) and once at night, waking up at
different times (02:00, 04:00, and 06:00) in rotation for two weeks in total. Three forced
expiratory maneuvers were recorded at each time point. PEF and FEV1 were found to be
equally sensitive to detection of circadian rhythm in stable asthmatics and normal controls,
with a significant circadian rhythm detected on 50% of all recorded days. The maximum
values of both PEF and FEV1 coincided at around 14:00 (Troyanov et al., 1994).
2.3.3 Short and long-term repeatability of spirometry
One of the earliest reports on reproducibility of spirometry in an occupational sample
examined 38 subjects exposed to small concentrations of beryllium followed for 18-24
months with spirometry completed at 6-month intervals. VC was documented to have the
best reproducibility of 0.104 liters or 2.1% and FEV1 0.113 liters or 3.0%. The relative
repeatability of FEV2 and FEV3 were better than for FEV1, although in absolute terms
their repeatability was poorer. MMEF values proved to be the least repeatable of the
variables evaluated (Dawson, 1966).
In  normal  adults  (n=10)  completing  spirometry  on  the  same day  of  the  week  for  six
weeks and on three separate days hourly, the variation in any subject for FEV1 and FVC
over the study period was considerably less than for MEF50, MEF75, or FET (Cochrane
et al., 1977). FVC varied within subjects 1.8% hourly and 2.9% daily or weekly. FEV1
varied 2.3% hourly, 2.9% daily, and 3.4% weekly. The corresponding figures for FET
were 9.4%, 12.0%, and 13.0% (Cochrane et al., 1977). Correspondingly, McCarthy and
coworkers (1976) studied 12 normal subjects ten times each day and found a coefficient of
variation  for  within-day  measurements  of  3% for  both  FVC and FEV1 and  5% for  FVC
and 7% for FEV1 for week-to-week measurements.
Based on an analysis of earlier published studies, the upper limit of intraindividual
variability in spirometry was assessed to be an increase in excess of 11% in FVC, 13% in
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FEV1, or 25% in FEF25-75%, representing a significant change from baseline, e.g. in
bronchodilation testing (Pennock et al., 1981). When following patients over a longer
period, the week-to-week change of FVC or FEV1 must be greater than 20-25% or the
change in FEF25-75% greater than 30% to be considered significant (Pennock et al.,
1981).
Daily spirometry on five consecutive days in 15 normal subjects yielded mean
individual standard deviations of 0.102 liters for FEV1 and 0.119 liters for FVC. The mean
for individual CoV for both FEV1 and FVC was 2.8% (Rozas & Goldman, 1982). In the
same study, patients with airflow obstruction demonstrated significantly higher variability
and authors concluded that FEV1 would need to change 17% and FVC 15% for the change
to be considered significant in patients with airflow obstruction, whereas a greater than 5%
change in either FEV1 or FVC would be significant in normal subjects (Rozas &
Goldman, 1982).
In two separate studies, Tweeddale and coworkers (1984, 1987) assessed the within-
subject variability of FEV1 in normal and obstructive subjects. In normal subjects and a
small group of patients with restrictive ventilatory defects, they demonstrated over a wide
range of FEV1 that its short-term variability was rather constant and suggested a criterion
of response of 190 ml or more in normal subjects (Tweedale et al., 1984). In a prospective
sample of 150 patients with OAD, the natural variability over a 20-min period when
expressed in absolute terms was similar over the entire range of FEV1 (0.5 – 4.7 liters) and
differed insignificantly from that found in normal subjects. The increase in FEV1 and VC
required to exclude natural variability with 95% confidence in these patients was 160 ml
and 330 ml, respectively. Natural variability of relative change in FEV1 was negatively
correlated with the level of FEV1 recorded (Tweeddale et al., 1987).
The long-term variability of flow-volume spirometry is affected by aging and
potentially disease-related decreases in measured variables (Glindmeyer et al., 1982;
Dirksen et al., 1998; Jensen et al., 2007). Although not directly repeatability issues, two
phenomena warrant mentioning in this regard: the horse-racing effect and regression
towards the mean (Rijcken et al., 1997). The horse-racing effect refers to subjects
observed to have a lower-than-average lung function at one measurement usually having
faster decline in lung function in longitudinal follow-up (Burrows et al., 1987). Regression
towards the mean is caused by the interaction of change with the initial level of lung
function (Rijcken et al., 1997). This means that subjects having below average values at
the first measurement, are more likely to have closer to average values in the repeated
measurements due to the inherent measurement variability of multiple measurements.
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2.4 Assessment of bronchodilation response in flow-volume
spirometry
Bronchodilation response refers to the change in airway caliber as a result of inhaled
bronchodilating medication that causes improvements in flow or volume variables
detectable by pulmonary function tests, e.g. flow-volume spirometry.
Studies on bronchodilation have been conducted on various samples and with differing
bronchodilating medications, dosages, and delivery methods, making comparisons
difficult. Again, the older studies from 1960s and 1970s are less comparable due to
methodological differences (Olsen & Hale, 1968; Boushy, 1972; Skinner & Palmer, 1974;
Sobol et al., 1974; Popa & Werner, 1976; Fish & Permutt, 1978; Fairshter & Wilson,
1980).
Standardization of the interpretation of reversibility testing started already in the 1970s
(Snider et al., 1974), but wide differences prevailed. Although the 2005 ATS/ERS
standard recommended the use of 400 µg of salbutamol aerosol, it still left the choice of
medication used open for clinical consideration (Pellegrino et al., 2005).
2.4.1 Selection of variables and indices
A  number  of  possible  indices  have  been  evaluated  in  search  of  a  good  measure  of
bronchodilation, but in reality the clinical question to be answered affects the assessment.
Different indices might be appropriate to answer different clinical or research problems. A
listing of indices with the formulas used for calculation in the literature is shown in Table
1.
Table 1. Indices used in the literature for calculation of FEV1 bronchodilation response
Index Abbreviation Mathematical formula for calculation
absolute change absolute FEV1post – FEV1pre
change as a percentage of prebronchodilator value % initial FEV1post – FEV1pre * 100FEV1pre
change as a percentage of predicted value % predicted FEV1post-FEV1pre * 100FEV1predicted
change as a percentage of the maximal absolute response ever
recorded (during the study period) % maximal
FEV1post – FEV1pre* 100
change of FEV1max
change as a percentage of predicted value minus prebronchodilator
value % possible
FEV1post – FEV1pre  * 100
FEV1predicted – FEV1pre
change as a percentage of the highest postbronchodilator value ever
recorded during the study period minus prebronchodilator value % achievable
FEV1post-FEV1pre * 100
FEV1max-FEV1pre
standardized residuals sdr [(FEV1post-FEV1predicted) - (FEV1pre - FEV1predicted)]              sd of FEV1predicted
percentage with respect to the baseline modified cf FEV1post-FEV1pre * 100 * 2FEV1pre+FEV1post
FEV1pre= prebronchodilator FEV1; FEV1post=postbronchodilator FEV1; FEV1predicted=reference value for FEV1 for the subject
(Fish & Permutt, 1978; Dompeling et al., 1992; Rodriguez-Carballeira et al., 2007)
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In Europe, the 1993 standard (Quanjer et al., 1993) advocated the use of change as a
percentage of the predicted value for both FEV1 and  FVC  as  a  measure  of  significant
bronchodilation. It has been debated that the percentage of the predicted value has a lower
correlation with predilator values but a high sensitivity and specificity in separating
asthma and COPD (Weir & Burge, 1991; Brand et al., 1992). Analysis of variance using
change as a percentage of the predicted value and covariance analysis of pre- and
postbronchodilator FEV1 have been demonstrated to offer the best performance, especially
in clinical trials (Goedhart & Zanen, 2002).
In fact, most studies have focused on the differential diagnosis of COPD and asthma.
COPD is characterized and defined as an “obstruction that is not fully reversible” (Global
Initiative  for  Chronic  Obstructive  Lung  Disease;  Rabe  et  al.,  2007).  However,  many
patients with COPD demonstrate partial reversibility, and others have both asthma and
COPD (Kesten & Rebuck, 1994; Jeffrey et al., 1999; Ryu & Scanlon, 2001; Mannino,
2008; Shaya et al., 2008). Patient selection in these studies is very difficult since selection
fundamentally affects the outcome. The procedure and in particular the inspiratory
maneuver preceding forced expiration should be standardized, especially with COPD
patients (Eliasson & Degraff, 1985; Reddy et al., 1996; Pellegrino et al., 1998; Santus et
al., 2003). Recently, Tashkin and coworkers (2008) found up to 60% of patients with
COPD to test reversible following a longer wash-out period of maintenance therapy.
Additionally, the choice of bronchodilating medication used in the test might have a
greater influence in COPD patients (Dorinsky et al., 1999; Joos et al., 2003; Tashkin et al.,
2008).
Meslier and coworkers (1989) investigated 20 subjects with chronic bronchitis and 32
subjects with stable airways obstruction and measured forced expiratory flows before and
after increasing doses of salbutamol to differentiate asthma from chronic bronchitis. Using
discriminant analysis, FEV1 was found to be the most effective index of forced expiration
to discriminate among the mechanisms of airflow obstruction in asthma and chronic
bronchitis (Meslier et al., 1989).
Earlier, Light and coworkers (1977) evaluated 20 adults with reversible airways
obstruction defined as 15% improvement in FEV1 following 150 µg isoproterenol and
found FEV1 to be the best test for evaluating the response to bronchodilators and that the
use  of  MMEF  or  body  pletysmography  did  not  allow  more  conclusions  than  the  use  of
FVC and FEV1 alone. On the other hand, body pletysmography was observed to result in a
greatest  number of significant responses in patients with OAD (COPD or asthma),  when
compared with spirometry (FVC and FEV1)  and impulse oscillometry (van Noord et  al.,
1994). The study did not, however, take into consideration the natural variability of the
measurements compared. Oscillometry was insensitive in subjects with severe baseline
obstruction, who were more likely to respond in improvements in FVC (van Noord et al.,
1994; Zerah et al., 1995; Houghton et al., 2004a, 2004b; Rodriquez-Carballeira et al.,
2007; Schermer et al., 2007), but results from other modalities have lacked general
usability (Hadcroft & Calverley, 2001).
Dompeling and coworkers (1992) examined 72 asthmatics and 111 subjects with
COPD  on  six  test  occasions  over  two  years  and  compared  the  bronchodilation  response
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achieved at each visit using 400 µg of salbutamol and 80 µg of ipratropium bromide. They
compared six different indices for their ability to differentiate between asthma and COPD,
for the reproducibility of the bronchodilation response, and dependence on
prebronchodilator FEV1. Dependence on prebronchodilator FEV1 implies that responses
are not directly comparable between subjects. The reproducibility of bronchodilation
response is a more complex issue since reversibility of obstruction is asthma is
characteristically fluctuating, hence changes in measurements day-to-day or week-to-week
can change as disease state changes without any changes in measurement accuracy. They
found the “% possible” or change as a percentage of the predicted minus
prebronchodilator value and “% achievable” or change as a percentage of the maximal
postbronchodilator minus prebronchodilator value to depend least on prebronchodilator
FEV1 and to have the highest reproducibility, whereas “% initial” or change as a
percentage of the prebronchodilator value was the most dependent on the
prebronchodilator lung function and had the worst reproducibility. One of the inclusion
criteria of the study was that subjects could not use any corticosteroids or cromoglycate
during the study, which would quite fundamentally affect bronchodilation responses
during the two years of the study, at least in the participating asthmatics (Dompeling et al.,
1992).
The use of the ratio of change in FEV1 to change in FVC to differentiate between flow
responders and volume responders has been suggested, with a ratio over one signifying
predominantly flow response (Paré et al., 1983; de la Hoz, 2002). The use of partial
expiratory flow-volume curves has been evaluated in the assessment of bronchodilation
response, with potentially promising results in early studies (Barnes et al., 1981), but
ultimately found not to bring any additional benefit in differentiating between healthy and
asthmatic responses (Berry & Fairshter, 1985).
2.4.2 FEV1 response to bronchodilation
Studies on healthy adults
Watanabe and coworkers (1974) investigated 75 subjects aged 20-81 years who were
classified as ”normal” based on subjects’ self-reported status. Of these, 12 men and 4
women were current smokers with a smoking history of under 10 pack-years. All of the
subjects denied having ”smoker’s cough”. Bronchodilation testing was undertaken with 3
or 4 deep inhalations of an aerosol mist from a Bronkometer pocket nebulizer, with each
dose containing isoetharine 350 µg, phenyl ephrine 70 µg and thenyldiamine 30 µg.
Average FEV1 changed from 3.610 liters to 3.692 liters, which is +2.5% (SD 3.9%).
Twelve of the subjects showed a decrease in FEV1 despite a concomitant increase in
specific conductance (sGaw). FVC remained virtually unchanged in light of the mean
value of 0.2% (SD 2.5%)(Watanabe et al., 1974). From this data, Sourk and Nugent
(1983) have since recalculated 95% confidence intervals, finding changes in excess of
5.2%, 10.5%, and 49% in the FVC, FEV1, and FEF25-75%, respectively, occurring in
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only 5% of normal subjects. Watanabe and coworkers (1974) also showed that
bronchodilation response tended to decrease with aging and suggested that this could be
due to the decreasing sensitivity of bronchial smooth muscle ?-adrenergic receptors as
subjects age. The larger the bronchodilation response, the greater its variation in long-term
follow-up (Watanabe et al., 1974).
In a small group of normal controls (n=5), FEV1 increased on average 4.0% with 200
µg salbutamol (Holmes et al., 1978). A similar magnitude of change was reported in a
dose-response study, where responses to 100 µg, 200 µg and 800 µg of salbutamol were
4.1%, 3.8%, and 4.7% from baseline, respectively (Houghton et al., 2004a).
Population studies
Lorber and coworkers (1978) reported one of the first population studies on
bronchodilation response in 1063 subjects from the general population. However, since no
physician was in attendance during spirometry, the study protocol limited bronchodilation
testing completed in subjects without tachycardia, any history suggesting cardiac disease,
hypertension, diabetes mellitus, hyperthyroidism, pregnancy, lactation, or regular use of
bronchodilator medications. Subjects with lower baseline FEV1 tended to have larger
bronchodilating responses to isoproterenol. Subjects with better-than-average lung
function initially showed no systematic improvement after isoproterenol, and the authors
identified a level of lung function above which a ”zero mean change group” was formed.
They defined significant bronchodilator response as a degree of improvement greater than
that observed in 95% of the ”zero mean change group”, being 0.315 liters or 7.7% change
in FEV1 and 0.403 liters or 10.7% change in FVC (Lorber et al., 1978).
Dales and coworkers (1988) studied a population sample of 2,609 subjects (1,982
adults) with spirometry and bronchodilation testing using 500 µg of terbutaline sulfate.
The population mean for change in FEV1 was 68 (SD 129) ml or 2.1% (4.3%) from the
baseline. In the healthy subgroup, change in FEV1 was 57 (128) ml or 1.8% (4.0%). The
95th percentile of change in FEV1 in the healthy subgroup was 291 ml or 9%. In absolute
change of FEV1, bronchodilation response and the corresponding 95th percentile were
higher in men, and within age groups it was greater in taller than in shorter participants. A
negative association between predicted FEV1 and bronchodilation response was observed
with higher response detected in subjects with reduced FEV1 (Dales et al., 1988).
Lehmann and coworkers (2007) investigated a general population sample, inviting all
adults aged 47-48 and 71-73 years in Bergen, Norway. Subjects without anti-asthmatic
medication and completing acceptable flow-volume spirometry with salbutamol
reversibility testing (n=3,088) were included in a study analyzing the role of symptoms in
prediction of bronchodilation response. FEV1 reversibility ?12% and ?200 ml was
obtained in 2% of middle-aged and 4% of elderly subjects. Wheezing without cold,
dyspnea climbing two flights of stairs, and morning cough predicted an increased FEV1
bronchodilator response, whereas chronic cough had an inverse relationship (Lehmann et
al., 2007). In a separate report, the importance of anthropometric variables and smoking
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history in the response to salbutamol found change in FEV1 in the middle-aged of 0.071
(SD 0.122) liters or 2.4% (4.1%) baseline and in the elderly 0.064 (0.113) liters or 3.3%
(5.9%) from baseline (Lehmann et al., 2006). Female gender, old age, and BMI were
positively correlated with the relative change measures. In linear regression analysis,
smoking was found to be the strongest determinant of bronchodilation response, but all of
the variables together explained only 7-16% of measurement variability, and hence, are of
minor importance in the interpretation of the test (Lehmann et al., 2006).
Johannessen and coworkers (2005, 2006) studied a sample (n=2,235) of the general
population in two reports on prevalence and risk factors of COPD and on
postbronchodilator reference values for flow-volume spirometry. In men, the mean change
in FEV1 was 0.145 (SD 0.134) liters in 27- to 39-year-olds, 0.078 (0.120) liters in 40- to
59-year-olds, and 0.034 (0.178) liters in 60- to 82-year-olds. For women, the
corresponding values were 0.115 (0.101) liters, 0.056 (0.095) liters, and 0.046 (0.081)
liters. Bronchodilation response decreased with aging, with no gender difference
(Johannessen et al., 2006).
Studies on patient groups
Bronchodilation response has been extensively investigated in different patient groups,
especially in various clinical trials. The design of studies varies greatly, with varying
numbers of subjects with asthma and/or COPD, diagnostic criteria, degrees of obstruction,
and different baseline treatment allowed. In this summary, only studies focusing on
bronchodilation response and its determinants are considered.
Reversibility testing conducted with 250 µg of isoproterenol in 985 subjects with
COPD who were evaluated and followed for three years in a trial of intermittent positive
pressure breathing was reported to be on average 15% relative to baseline or 5% relative
to  predicted  normal  for  subjects  who  were  able  to  abstain  from  bronchodilators  for  6  h
previously (Anthonisen et al., 1986). All subjects had baseline FEV1<60% predicted,
FEV1/FVC<60%, and TLC ?80% predicted.
Guyatt and coworkers (1988) studied 24 subjects (one woman) with chronic airflow
limitation and tested the ability of acute change in FEV1 to predict long-term symptomatic
response to albuterol and theophylline. They found reproducibility of acute change in
FEV1 to be poor (ICC 0.17), and the change in FEV1 was not associated with symptomatic
response to either albuterol or theophylline (Guyatt et al., 1988). Their study was likely to
also include asthmatics based on current criteria since changes in FEV1 were on average
0.150 (0.09) liters or 19.7% (11.2%) from baseline. Initial FEV1 reversibility was under
25% in 19 and between 25-35% in 5 subjects (Guyatt et al., 1988). Additionally, other
studies have shown that variability of spirometry is greater in subjects with low baseline
FEV1, and the subjects evaluated by Guyatt and coworkers had on average a baseline
FEV1 of 0.93 (0.34) liters. They concluded that acute response to inhaled ?2-agonist is not
useful for identifying patients with chronic airflow limitation likely to benefit from
bronchodilator treatment (Guyatt et al., 1988).
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In a population sample of 123 volunteers (90 men, 33 women) consisting of current or
ex-smokers experiencing breathlessness who responded to an advertisement for lung
function testing had a median FEV1 response to 400 µg salbutamol from the baseline of
10.4% or 165 ml in current smokers and 9.8% or 140 ml in ex-smokers (Reid et al., 2003).
A significant inverse relationship between prebronchodilator FEV1 and change in FEV1
expressed as a percentage increase was found, but also a positive relationship between
absolute change and prebronchodilator FEV1. Median change in FVC was 9.3% or 275 ml
in current smokers and 7.0% or 220 ml in ex-smokers. Inhaled corticosteroid (ICS) use
was  reported  by  58%  of  study  subjects,  and  the  use  of  ICS  was  weakly  correlated  with
lower prebronchodilator FEV1 (r=-0.2) and greater change in FEV1 (r=0.3) in
bronchodilation testing (Reid et al., 2003).
Since measurement repeatability and disease state can fluctuate within a subject
between measurements, the significance of each patient’s response to inhaled albuterol has
been assessed with a statistical model taking into consideration five measurements at
baseline, following inhaled saline solution (acting as a placebo control) and albuterol (5
mg/ml four breaths from nebulizer) in this order (Hansen et al., 1993). In very severe to
severe obstruction, relative change of FEV1 was found to identify significantly more
“significant” responders, when saline was used as the comparison, which was suggested as
one potential explanation for the discrepancy between symptom relief and demonstrated
reversibility in spirometry. Bronchodilation response has been reported to be dependent on
baseline values, especially in newly referred patients with asthma, but this dependency
was less strong in bronchitis and even weaker in subjects with emphysema (Goedhart et
al., 2004).
Schermer and coworkers (2007) studied 2,210 patients with varying degrees of COPD
and assessed the relative role of flow and volume responses after salbutamol. Average
change in FEV1 was 0.180 (SD 0.150) liters or 6.3% (5.1%) of predicted. In their patient
sample, subjects with mild COPD had greater flow responses (change in FEV1), whereas
in subjects with severe COPD the bronchodilation response was greater in volume (change
in FVC). Changes in expiratory time were not registered in their study. The authors
hypothesize that the difference could be explained by the higher degree of loss of lung
elastic recoil and/or compression of the smaller airways due to enlarged air spaces
associated with progression of COPD to more severe stages (Schermer et al., 2007).
2.4.3 FVC response to bronchodilation
Assessment of changes in lung volumes during the bronchodilation test with flow-volume
spirometry is demanding. Bronchodilation may induce changes in lung volume
compartments, such as residual volume (RV) related to TLC, and changes in nonventilated
lung compartments (Gimeno et al., 1993; Pellegrino & Brusasco, 1997; O’Donnell, 2000;
O’Donnell et al., 2001). Flow-volume spirometry can only give suggestive evidence of
these changes.
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Girard and Light (1983) demonstrated that FVC responders in spirometry could be
divided into two major categories: true volume responders and those with prolonged FET
in postbronchodilator spirometry. Individuals with prolonged FET did not demonstrate
any significant change in FEV3 or FEV6 in postbronchodilator spirometry (Girard & Light,
1983). Prolongation of FET in bronchodilation testing has been suggested to also be due to
actual bronchodilation, but this has not been confirmed (de la Hoz, 2002; Tsai et al.,
2006).
 Ramsdell and Tisi (1979) studied retrospectively all patients referred to the pulmonary
function laboratory for spirometry and bronchodilation testing over a one-year period.
Isoproterenol 2.25 mg was used as the bronchodilator. Four types of response were
identified: no response, isolated volume, isolated flow, and dual response. These groups
were evaluated based on FEV1/FVC% or FEF25-75%, but because the groups were
defined by these two variables, even the isolated volume response group showed a mean
FEV1 response of +150 ml or 13%. However, the isolated volume responders had
significantly more severe airways obstruction than did the isolated flow responders
(Ramsdell & Tisi, 1979).
In the United States, the Intermountain Thoracic Society issued its own guidelines and
criteria for significant bronchodilation response. These criteria were more specific and
detailed and included also the assessment of FET in FVC bronchodilation, stating that for
a change in FVC to be significant, FET should not increase by >10% (Morris et al., 1984).
Smith and coworkers (1992) evaluated 100 subjects with suspected reversible airways
obstruction with the intent of elucidating mechanisms to explain the occasional
discrepancy between symptom improvement following bronchodilator therapy not
detectable in spirometry. Subjects received differing bronchodilating medication
(metaproterenol, isoproterenol, albuterol, or atropine in combination with ?-agonist) at
doses that were increased until subjects experienced side-effects of tremor or tachycardia.
They concluded that improvements in volume-related parameters may explain the
discrepancy in some patients and that FEF25-75% at baseline was higher in patients who
required pletysmography to identify response (Smith et al., 1992). However, in some
studies, body pletysmography was unable to identify more significant responses than
flow-volume spirometry (Light et al., 1977; Berger & Smith, 1988). This can be explained
by varying consideration of measurement repeatability in these studies.
Pellegrino and Brusasco (1997) have suggested that in some subjects with dynamic
hyperinflation in severe COPD bronchodilation could decrease functional residual
capacity and reduce the elastic work of breathing. The relationship between hyperinflation
and bronchodilation response to 200 µg of salbutamol was retrospectively studied in 281
subjects with severe hyperinflation (TLC>133%) and in 676 subjects with moderate
hyperinflation (115%<TLC<133%) (Newton et al., 2002). FEV1 improved in 26-33% of
patients, but VC increased in up to 76%. In the severely hyperinflated group, change in
FEV1 was on average 0.16 (SD 0.01) liters or 14.9% (SD 0.9%), the corresponding figures
for moderately hyperinflated individuals were 0.15 (0.01) liters and 11.0% (0.7%). Both
groups showed stronger FVC responses, with a mean increase of 0.34 (0.02) liters or
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15.6% (0.9%) in the severely hyperinflated group and 0.20 (0.01) liters or 9.1% (0.6%) in
the moderately hyperinflated group (Newton et al., 2002).
In subjects with emphysema and without reversibility in terms of change in FEV1
during the bronchodilation test (n=88), significant reductions in lung hyperinflation
(decrease in RV) were detected in 83%, with the greatest changes observed in those with
the most severe disease (O’Donnell et al., 2001). Similarly, subjects with expiratory flow
limitation showed significant decreases in functional residual capacity (FRC), associated
with increase in inspiratory capacity (IC). Thus, subjects with dynamic hyperinflation
despite having no improvement in expiratory flow, benefited through reduction of
hyperinflation that permitted them to breathe at a lower lung volume (Tantucci et al.,
1998).
Change in FEV3 has been shown to correlate well with change in FVC, although the
method used included a shorter MEFV maneuver, where subjects were not encouraged to
continue after 4 s (Hansen et al., 1993). Paré and coworkers (1983) studied 15 subjects
with asthma and used a change ratio of change in FEV1 divided  by  change  in  FVC  of
under one to signify volume response correlating with the presence of a marker of small
airways dysfunction, and they suggested a postbronchodilator recruitment of peripheral
airways as a possible explanation.
Of  ten  patients  with  COPD,  five  had  “isolated  volume  response  to  bronchodilators”,
i.e. improvement in only FVC, whereas five responded in both FEV1 and FVC. Small
airway caliber was measured by high-resolution computed tomography (HRCT). In
subjects with FEV1 and FVC response, the airway caliber increased with the cube root of
increase in lung volume, but it was unchanged or even decreased in all but one of the FVC
responders. The authors suggested longitudinal traction or space competition as potential
underlying mechanisms. Subjects with only FVC response were reported to have more
severe emphysema (Cerveri et al., 2000).
In a Norwegian population material studied for postbronchodilator reference values in
flow-volume spirometry, the mean changes in FVC for men following 0.3 mg of
salbutamol were reported as 0.010 (SD 0.137) liters in 27- to 39-year-olds, -0.022 (0.131)
liters in 40- to 59-year-olds, and -0.026 (0.132) liters in 60- to 82-year-olds. The
corresponding mean values for women were -0.009 (0.110) liters, -0.021 (0.111) liters,
and -0.001 (0.103) liters (Johannessen et al., 2006).
In conclusion, bronchodilator reversibility is a fundamental feature of asthma, which
also reflects treatment response. Interpretation of studies conducted with patients with
OAD  should  take  into  consideration  the  proportion  of  asthmatics  included.  COPD  is
characterized by airflow limitation that is not fully reversible. However, with longer wash-
out periods of previous medication and combined use of ?-sympatomimetic and
anticholinergic bronchodilating medication, Tashkin and coworkers (2008) have recently
found up to 60% of COPD patients reversible on ATS/ERS criteria. Also in patients with
COPD, bronchodilator reversibility varies with time (Vestbo & Hansen, 2001; Calverley
et al., 2003; Anthonisen et al., 2005; Hansen & Vestbo, 2005). Earlier, reversibility was
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associated with poor outcome and disease progression (Kanner, 1984; Postma et al., 1985,
1986), and in other studies with potential treatment response to inhaled corticosteroids
(Nisar et al., 1990, 1992; Kerstjens et al., 1993). Airway hyperresponsiveness in
asymptomatic subjects has been associated with increased risk of developing both asthma
and COPD, and an increased COPD mortality (Hospers et al., 2000; Vestbo & Hansen,
2001; Brutsche et al., 2006). Hansen and coworkers (1999) have shown that treatment
response has an effect on mortality of COPD as far as the level of FEV1 is concerned, but
that this effect seems to be due to the role of FEV1 as a variable associated with mortality
and morbidity and not due to other treatment effects of the medications under assessment.
2.5 Prevalence of obstructive airways disease in adults in Finland
Prevalence of a disease in a population is defined as the total number of cases in the
population at a given time divided by the number of individuals in the population.
Conversely, incidence is defined as the number of new cases of a disease within a given
time period. Hence, prevalence is a measurement of all individuals affected by the disease
at a given point in time, regardless of the date of contraction; whereas incidence is a
measurement of individuals who contract the disease during a specified time interval.
The earliest population studies on the prevalence of obstructive airways disease in
Finland date back to the 1960s and 1970s. Järvinen and coworkers (1960a, 1960b) found a
prevalence of obstructive pulmonary emphysema of 8.7% and 3.7% for men and women,
respectively.  Huhti  (1965)  reported  for  a  small  rural  community  prevalence  rates  for
asthma of 0.5% and 1.6%, emphysema 10.0% and 2.3%, and chronic bronchitis 28.2%
and 5.8% for men and women, respectively. These initial studies included chest x-rays and
clinical examination in addition to questionnaire information. In 1970, Alanko published a
questionnaire study for the same rural community studied earlier by Huhti (1965). The
prevalence of asthma was lower in young adults (0.2%) than in the middle-aged (3.3%),
with a population prevalence of 1.2% (Alanko, 1970).
Since these early studies, increasing rates of asthma prevalence were reported during
the 1980s and 1990s. The prevalence of asthma in young conscripts has been followed
from 1926, with the prevalence remaining under 0.1% until the 1960s. The prevalence of
asthma started rising from 0.29% in 1966 to 1.79% in 1989 and 3.45% in 2003 (Haahtela
et al., 1990; Latvala et al., 2005). However, between 1989 and 2003 the asthma-cases
seemed to have become milder and better controlled (Latvala et al., 2005). This has been
attributed to the nationwide asthma-programme 1994-2004 (Haahtela et al., 2006). In a
nationally representative sample, the prevalence of asthma was reported as 4% in 1988
(Vesterinen et al., 1988).
In a study analyzing the role of atopy and smoking in the development of chronic
bronchitis, the prevalence was lowest in nonatopic nonsmokers (4.1%), increasing to
10.1% in atopic nonsmokers, 10.6% in nonatopic smokers, and 25.7% in atopic smokers
(Terho et al., 1987). Atopy was found to predispose to chronic bronchitis (Terho et al.,
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1995). In a large twin study of 13,888 subjects, the age-adjusted cumulative incidence of
asthma was between 1.7% and 2.2%, and the heritability was estimated at 35.6%
(Nieminen et al., 1991).
Isoaho and coworkers (1994a, 1994b) reported on a rural community sample aged 64
years or over and defined obstruction as FEV1/FVC<0.66. The prevalence of COPD was
12.5% for  men and  3.0% for  women.  Among current  smokers,  the  prevalence  of  COPD
was 35% for men and 13% for women, whereas never-smokers had a prevalence of 2%.
The prevalence of current asthma was 2.9% in men and 3.8% in women.
Hedman and coworkers (1999) reported for a postal questionnaire study population a
nonresponse-adjusted prevalence of doctor-diagnosed asthma of 4.4% and COPD of 3.7%,
with the definition of asthma or COPD varying slightly from current practice. In a nation-
wide study (n=7,217), von Hertzen and coworkers (2000) found an age-adjusted
prevalence of chronic bronchitis and/or emphysema of 22% among men and 7% among
women, and clinically relevant airways obstruction in 11% of men and 5% of women.
Karjalainen and coworkers (2001) reported that 29% of male asthma cases and 17% of
female asthma cases were associated with occupation, with the risk being highest in
agricultural, manufacturing, and service occupations. In another study on occupational
influences, Jaakkola and coworkers (2003) reported increased asthma risks in traditional
industries, in forestry, and in several nonindustrial occupations, such as female wait-staff,
cleaners, and dental workers.
Pelkonen and coworkers (2006) reported a 30-year cumulative incidence of chronic
bronchitis and COPD of 42% and 32%, respectively, in continuous smokers, compared
with 26% and 14% in ex-smokers and 22% and 12% in never-smokers. Subjects with
chronic bronchitis had on average 252 ml lower FEV1 than those without chronic
bronchitis, the change being most prominent in symptomatic subjects and smokers. In
subjects with chronic bronchitis, the hazard ratio for all-cause mortality was increased to
1.30 (95% CI 1.02-1.65) in the 40-year mortality follow-up between 1960 and 2000
(Pelkonen et al., 2006).
In the FinEsS studies, Kotaniemi observed from Finnish Lapland a self-reported
physician-diagnosed asthma prevalence of 6.0% (Kotaniemi et al., 2001, 2002; Lindström
et al., 2001). Based on spirometry, 9.4% of the population sample had COPD using GOLD
criteria, with the risk of COPD increasing significantly with age, smoking pack-years, and
family history of OAD. Among subjects with over 40 smoking pack-years, the prevalence
of COPD was over 50%, and, furthermore, early start of smoking was identified as a
strong risk factor for the disease (Kotaniemi et al., 2005). In Helsinki, the prevalence of
physician-diagnosed asthma was 6.6% based on the 1996 postal questionnaire study
(phase I) (Pallasaho et al., 1999, 2002; Pallasaho, 2006).
In summary, the population prevalence of asthma has increased in Finland, as in most
Western countries, with physician-diagnosed asthma reported in 6% of subjects, and fixed
obstruction fulfilling COPD diagnostic criteria (GOLD) in approximately 9% of subjects.
In addition to the nationwide asthma programme (Haahtela et al., 2006), Finland also has
an ongoing Action Programme on chronic bronchitis and COPD (Pietinalho et al., 2007).
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3 Aims of the study
1. To evaluate FET and its spirometric and anthropometric determinants in a nonselected
adult population sample and in healthy nonsmokers (I)
2. To evaluate the intrasession repeatability of FET and FEV6 and the determinants of
variability in the general adult population (II)
3. To determine the distribution and range of bronchodilation response in terms of changes
in FEV1 in a general adult urban population and in a subgroup of healthy asymptomatic
nonsmokers to identify normal response and its anthropometric and spirometric
determinants (III)
4. To assess concurrent variations in FEV6, FVC, and FET in the bronchodilation test in a
general population sample of adults using flow-volume spirometry and to evaluate FVC
and FEV6 response to bronchodilator (IV)
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4 Materials and methods
4.1 The FinEsS study design and study subjects
The FinEsS study is a collaborative study of clinical epidemiology of respiratory health
between Finland (Fin), Estonia (Es), and Sweden (S). In Finland, research has been
conducted in Helsinki, Southern Finland, and in Kemi, Northern Finland. In Estonia, study
centers are located in Tallinn, Narva, and Saaremaa. In Sweden, studies have been
conducted in Norrbotten, Stockholm, and Örebro. Figure 4 presents the study areas.
Figure 4 Map showing FinEsS study areas (Pallasaho, 2006)
In 1995, a random sample of 8,000 individuals from the Finnish Population Registre
Center stratified by gender and 10-year age cohorts was selected to represent the adult
population aged 24-69 years in Helsinki. In the first phase, a postal questionnaire
(Pallasaho, 2006) that included questions about respiratory health was sent to subjects.
Altogether 6,062 individuals, 2,600 men and 3,462 women, responded. Eighty-eight
individuals were not reached (mail returned repeatedly), and 4 individuals had died. The
response rate corrected to the reachable portion was 76.8%. Young men and individuals of
foreign descent, as judged by a non-Scandinavian name, were more likely not to respond
to the postal survey. Response rate by gender and age cohort is shown in Figure 5.
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Figure 5 Response rate in FinEsS-Helsinki phase I stratified by gender and age
In 2000, a further random sample of 1,200 subjects stratified by age and gender was
selected from the original postal questionnaire responders to participate in the subsequent
clinical phase of the study. Since the original mailing of the postal questionnaire, 34
subjects had died and 27 subjects had no current mailing address in the Population
Register. Four subjects were reached but deemed unable to participate due to severe
illness, e.g. terminal cancer and previous severe stroke. In total, 643 individuals
participated from 2001 – 2003 in the clinical studies. The response rate in phase II
corrected with the nonreachable individuals was 56.7%.
A nonresponder analysis was conducted to assess the postal questionnaire information
for responders and nonresponders in phase II. Nonresponders were more often young male
smokers. Responders did not significantly differ from nonresponders in terms of
symptoms or previous diagnoses of OAD when assessed with the Chi-squared test. The
study sample consisted of the 643 individuals participating in phase II of the FinEsS-
Helsinki study. Figure 6 shows the age and gender distribution of the study subjects.
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Figure 6 Age and gender distribution of FinEsS-Helsinki phase II participants
Of the 643 subjects participating in the clinical study, ten were excluded from the
analysis based on unacceptable or missing spirometry data. Despite vigorous coaching,
acceptable and/or repeatable determinations were not obtained.  Data are reported only for
subjects with acceptable baseline spirometry (n=633). The study participants were on
average 49.2 (SD 13.0) years old, 169.6 cm (SD 94.3) in height, and had a BMI of 26.0
(SD 4.9) kg/m2. Older subjects were slightly shorter and older females had a higher BMI.
4.2 FinEsS II: the clinical study
Subjects were interviewed by one of the study nurses on the phone when making the
appointment for the pulmonary function test measurement. The subjects were informed
not to have the pulmonary function test measurements whilst recovering from any
respiratory infection. During the clinical visit, all subjects were interviewed using a
structured interview (see below), tested with flow-volume spirometry with
bronchodilation testing, and subjects under 61 years of age were tested with a skin-prick
test for common aeroallergens (Pallasaho, 2006; Pallasaho et al., 2006). Approximately
one-third of the subjects were further randomly selected to take part in a second study visit
the following day during which exhaled nitric oxide and histamine provocation testing
was undertaken. The results from skin-prick, exhaled nitric oxide, and bronchial
provocation testing are not reported here, and these methods are therefore not elaborated.
4.2.1 Structured interview
During the clinical visit, subjects were interviewed by a trained physician using a
structured interview (Kotaniemi et al., 2005; Pallasaho, 2006). The FinEsS questionnaire
is based on a questionnaire developed and validated in the Swedish Obstructive Lung
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Disease in Northern Sweden (OLIN) studies (Lundbäck et al., 1991, 1993; Torén et al.,
1993). It contains questions that originate from the British Medical Research Council
(BMRC) (Medical Research Council’s Committee on the Aetiology of Chronic Bronchitis,
1960), International Union Against Tuberculosis and Lung Disease (IUATLD) (Burney et
al., 1989a, 1989b) and European Community Respiratory Health Survey (ECRHS)
(European Community Respiratory Health Survey, 1996) questionnaires. The
questionnaire contains 162 questions that deal with general health, respiratory signs and
symptoms, diseases and medications, provoking factors, and risk factors for respiratory
diseases. The structured interview questions are listed in Appendix 1 with translations to
English.
Based on the questionnaire information, 18 men (6.9%) and 33 women (8.9%) had a
previous asthma diagnosis, whereas only 5 men (1.9%) and 16 women (4.3%) had a
previous COPD diagnosis. Although it is likely that some subjects with COPD might
report themselves as having asthma, it is clear that COPD is underdiagnosed. One man
and three women had previous diagnoses of both asthma and COPD. Chronic bronchitis
was reported by significantly more subjects: 19 men (7.3%) and 20 women (5.4%). Forty-
five men (17.2%) and 86 women (23.1%) reported regular or as-needed use of anti-
asthmatic or reliever therapy, with many of them not recognizing a previous diagnosis of
OAD. Inhaled corticosteroids were used irregularly by 2 men (0.8%) and 10 women
(2.7%) and regularly by 8 men (3.1%) and 16 women (4.3%). A family history of OAD
was reported by 43 men (16.5%) and 97 women (26.1%) (Chi-squared for gender
difference, p<0.01).
4.2.2 Flow-volume spirometry
All subjects attempted to complete flow-volume spirometry, if no contraindications were
present. A priori, recent respiratory or cardiac illnesses (<4 weeks), possible contagious
lung infections (tuberculosis), recent abdominal surgery, and inability to cooperate in the
testing were considered contraindications. Ten subjects were unable to complete
satisfactory flow-volume spirometry. One subject had severe mental retardation, and the
questionnaire was completed by her parent. One subject had a history of multiple strokes
and another subject had a recent respiratory infection (despite advance guidance).
All subjects were advised to continue any regular medication. Only peroral
antihistamine medication was to be discontinued for 3 days prior to the skin-prick testing,
if possible, but short-acting ?-sympatomimetics were to be withheld for 4 h and long-
acting ?2-sympatomimetics 12 h. Subjects were advised to refrain from smoking for at
least 4 h, from coffee, tea, and heavy eating for 2 h, and from alcohol for at least 1.5 days
prior to the study visit.
One flow-volume spirometer (VMax 20c, Sensor Medics, Yorba Linda, CA, USA)
was used for all measurements. Spirometry was undertaken with the subject seated using
nose clips and disposable bacterial filters. Two trained nurses performed all
measurements. The calibration of the spirometer was checked with a 3-liter calibration
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syringe (Sensor Medics®, Sensor Medics Corporation) once a day and whenever the
spirometer software requested calibration. The subjects were first instructed on the
measurement of slow vital capacity, which was repeated until three comparable measures
were attained with a maximum of eight maneuvers. The three best values were selected.
The subjects thereafter proceeded to forced expiratory maneuvers that were performed
according to ATS 1994 standard. Up to three comparable maximum expiratory flow-
volume maneuvers were recorded with a maximum of eight attempts. Inspiratory curves
were registered in conjunction with the expiratory curves whenever feasible.
The beginning of the measurement was determined by back-extrapolation for timing of
FET  and  timed  volumes  (FEVt). The end of the FET measurement is defined in the
spirometry software as the beginning of the end-expiratory plateau, which means that the
measured FET systematically slightly underestimates the duration of the maneuver. The
threshold  of  volume  change  detectable  by  the  spirometer  was  under  25  ml/s.  The  FET
reported  by  the  spirometer  software  (Vision  Software  05-2A;  VMax  System,  Sensor
Medics Corporation) was used.
Quality criteria for acceptable spirograms
The acceptability criteria for individual maneuvers were based on ATS 1994 standard.
These stipulated that the extrapolated volume (EV) in each of the accepted spirograms be
no greater than 150 ml or 5% of the respective FVC, whichever was greater. During the
clinical study, it was further decided that data from subjects with two acceptable curves
fulfilling the EV criterion and repeatability criteria (see below) could be used for some
analyses, despite the third curves having excessive EV. The data from curves with
excessive EV were not utilized in analyses.
Repeatability targets in the international standards have changed during the last years.
In the ERS 1993 standard (Quanjer et al., 1993), the two largest FVC and FEV1 were
required to be within 100 ml or 5%, whichever was greater, and the two largest PEF to be
within 10%. The ATS 1994 standard gave up measures relative to lung volume and set the
limit  for  the  two greatest  FEV1 and FVC at 200 ml (ATS, 1995). In the joint ATS/ERS
standard in 2005, the repeatability limit was further reduced to 150 ml, with the exception
of individuals with FVC<1.0 liter, when the limit was set at 100 ml.
During the design of the FinEsS studies,  there was a general  consensus to follow the
same methodology and standards in the different Nordic centers to ensure comparability.
In spirometry, the ATS 1994 standard was chosen. However, between the centers
differences still occurred. In Helsinki, the repeatability targets were set based on the
nationally accepted ERS 1993 standard, which was apparently chosen because the
absolute repeatability targets were tighter and the inclusion of PEF was considered
important. However, since the ERS standard included the use of a second criterion relative
to the measured volume, the repeatability criterion was in fact slightly less stringent than
the  ATS  criteria  for  subjects  with  high  FEV1 or  FVC.  Up  to  eight  successive  attempts
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were made to achieve three comparable curves that would fulfill the acceptability and
repeatability criteria.
Bronchodilation testing
All subjects also underwent bronchodilation testing unless specific predefined
contraindications or other compelling reasons were present. Contraindications for
bronchodilation testing included a history of significant cardiac arrhythmia and recent
angina pectoris. One subject was excluded from bronchodilation testing due to cardiac
symptoms following baseline spirometry and one subject on the grounds of history of
arrhythmia. In addition, three subjects declined to take the bronchodilating medication.
The subjects were given 0.4 mg of salbutamol aerosol (Ventoline® Evohaler,
GlaxoSmithKline, London, UK) in two separate doses through a spacer device
(Volumatic®, GlaxoSmithKline, London, UK). Subjects then remained seated for 15 min,
without smoking or consuming beverages other than water, after which a repeated
spirometry was performed in an identical fashion to determine the bronchodilation
response.
Evaluated spirometry variables and their selection
For all study subjects, the three best and comparable curves were selected for analysis
both from the pre- and postbronchodilation spirometry. All completed MEFV maneuvers
were saved in a computer file, but the data from the other curves were not used here. The
best curve was defined as the one with the highest sum of FEV1 and FVC of the accepted
three curves. The second best curve was the one with the second highest sum of FEV1 and
FVC. For analysis, largest forced vital capacity (FVC), forced expiratory volume in six
seconds (FEV6), and forced expiratory volume in one second (FEV1) were selected, and all
other flow-values were selected from the best curve. FET corresponding to the best FVC
and the best curve was selected.  In assessment of intrasession repeatability (II), all three
acceptable curves from prebronchodilation spirometry were collected. Subjects with
excessive EV in one of the three selected curves were excluded from these analyses (II).
In the population, baseline spirometry was analyzed with the reference values from
Viljanen and coworkers (1982). Baseline FVC, FEV1, and FEV1/FVC diminished with
advancing age. Detailed spirometry statistics from the baseline spirometry are shown in
Table 2.
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Table 2. Baseline spirometry statistics stratified by gender in the study population. Statistics
presented as mean (SD). Predicted values from Viljanen et al., 1982.
20-29 years 30-39 years 40-49 years 50-59 years 60-69 years 70-79 years 20-79 years
Women 27 84 70 97 68 26 372
FVC (liters) 4.06 (0.57) 4.00 (0.48) 3.82 (0.57) 3.37 (0.49) 3.10 (0.49) 2.61 (0.48) 3.55 (0.66)
FVC% predicted 96.1 (9.3) 96.1 (10.5) 99.5 (11.4) 99.3 (12.7) 104.2 (13.5) 101.2 (17.9) 99.5 (12.6)
FEV1 (liters) 3.37 (0.44) 3.27 (0.37) 3.00 (0.47) 2.56 (0.46) 2.35 (0.37) 1.99 (0.37) 2.78 (0.59)
FEV1% predicted 92.6 (10.1) 93.1 (9.9) 94.9 (12.5) 92.8 (15.1) 98.9 (12.5) 96.7 (18.2) 94.6 (13.1)
FEV1/FVC (%) 83.4 (5.3) 81.8 (5.0) 78.4 (6.2) 75.6 (7.6) 76.3 (6.4) 76.4 (8.0) 78.3 (7.0)
FEV1/FVC% predicted 96.5 (6.0) 97.1 (6.0) 95.4 (7.4) 93.3 (9.4) 95.3 (7.9) 95.9 (10.0) 95.3 (8.0)
Men 14 68 62 60 42 15 261
FVC (liters) 5.49 (0.58) 5.67 (0.79) 5.26 (0.72) 4.87 (0.75) 4.37 (0.88) 4.05 (0.59) 5.08 (0.91)
FVC% predicted 97.7 (8.5) 98.0 (10.6) 97.0 (10.1) 98.5 (12.7) 99.7 (18.6) 100.0 (11.4) 98.3 (12.4)
FEV1 (liters) 4.35 (0.59) 4.46 (0.63) 4.13 (0.59) 3.67 (0.65) 3.11 (0.89) 3.08 (0.55) 3.90 (0.83)
FEV1% predicted 91.4 (11.8) 94.4 (10.8) 94.9 (11.0) 93.0 (15.2) 87.9 (23.8) 93.7 (15.0) 93.0 (15.0)
FEV1/FVC (%) 79.2 (7.8) 78.7 (5.4) 78.6 (5.3) 75.3 (7.3) 70.5 (11.7) 75.9 (4.8) 76.5 (7.8)
FEV1/FVC% predicted 93.7 (9.5) 96.5 (6.6) 97.9 (6.6) 94.2 (9.0) 87.5 (14.7) 93.3 (5.9) 94.5 (9.6)
Age group
4.3 Definitions
4.3.1 Smoking definitions
Smoking was defined in the questionnaire as smoking at least one cigarette per week or
four cigarettes per month. An ever-smoker was anyone who had smoked regularly for at
least  one  year.  Current  smokers  included  subjects  that  were  smokers  at  the  time  of  the
study  or  had  quit  smoking  within  the  last  12  months.  Former  smokers  were  required  to
have abstained from smoking for more than 12 months. Never-smokers were defined as
those who had never regularly smoked for one year or more. Smoking pack-years were
calculated for ever-smokers. For cigar smokers, a conversion factor of one cigar
corresponding to 7 cigarettes was used as an approximation.
Of the study sample, 98 men (37.5%) and 194 women (52.2%) were lifetime never-
smokers. Smoking was more common in men across the age groups, with the exception of
30- to 39-year-olds, in which group never-smokers made up 50% of both men and women.
Mean smoking pack-years was also greater in men in all age groups.
Current environmental tobacco smoke (ETS) exposure in general was reported by 47
men (18.1%) and 64 women (17.3%). Previous ETS in the home was reported by 47.5%
of  men and  49.7% of  women,  whereas  current  ETS at  home was  reported  by  6.9% and
9.5% of men and women, respectively. Previous and current ETS at home was more
prevalent in women, particularly in older age groups. At work, 10.8% of men and 3.5% of
women reported continuing ETS exposure. Exposure to occupational ETS was more
prevalent in older age groups, clearly influenced by the strict antismoking legislation
enacted in 1995 that prohibits smoking in offices and public places in Finland.
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Table 3. Descriptive statistics of anthropometric and smoking history of the study sample
stratified by gender and age groups. Data presented as mean (SD) unless otherwise
indicated.
20-29 years 30-39 years 40-49 years 50-59 years 60-69 years 70-79 years 20-79 years
Women 27 84 70 97 68 26 372
height (m) 1.66 (0.07) 1.67 (0.05) 1.65 (0.06) 1.63 (0.06) 1.61 (0.05) 1.58 (0.05) 1.64 (0.06)
BMI (kg/m2) 24.2 (5.4) 24.4 (5.4) 25.2 (5.2) 26.3 (5.2) 27.0 (4.3) 27.7 (5.7) 25.7 (5.2)
never-smokers n (%) 17 (63.0%) 42 (50.0%) 32 (45.7%) 42 (43.2%) 41 (60.3%) 20 (76.9%) 194 (52.2%)
former-smokers n (%) 4 (14.8%) 17 (20.2%) 17 (24.3%) 26 (26.8%) 18 (26.5%) 3 (11.5%) 85 (22.8%)
current smokers n (%) 6 (22.2%) 25 (29.8%) 21 (30.0%) 29 (29.9%) 9 (13.2%) 3 (11.5%) 93 (25.0%)
pack-years mean (s.d.) 1.4 (3.8) 4.3 (6.2) 6.4 (10.6) 10.8 (16.1) 9.2 (14.9) 8.3 (18.1) 7.4 (13.0)
under 10 pack-years n (%) 9 (33.3%) 26 (31.0%) 20 (28.6%) 20 (20.6%) 5 (7.4%) 1 (3.8%) 81 (21.8%)
10-29.9 pack-years n (%) 1 (3.7%) 16 (19.0%) 13 (18.6%) 23 (23.7%) 15 (22.1%) 1 (3.8%) 69 (18.5%)
30 pack-years or more n (%) 0 (0.0%) 0 (0.0%) 5 (7.1%) 12 (12.4%) 7 (10.3%) 4 (15.4%) 28 (7.5%)
Men 14 68 62 60 42 15 261
height (m) 1.78 (0.04) 1.81 (0.06) 1.79 (0.06) 1.77 (0.06) 1.74 (0.06) 1.74 (0.07) 1.78 (0.07)
BMI (kg/m2) 24.6 (5.1) 26.6 (4.5) 26.0 (3.9) 27.1 (4.9) 26.5 (3.6) 26.9 (2.5) 26.5 (4.3)
never-smokers n (%) 6 (42.9%) 34 (50.0%) 22 (35.5%) 17 (28.3%) 13 (31.0%) 6 (40.0%) 98 (37.5%)
former-smokers n (%) 4 (28.6%) 11 (16.2%) 10 (16.1%) 20 (33.3%) 22 (52.4%) 7 (46.7%) 74 (28.4%)
current smokers n (%) 4 (28.6%) 23 (33.8%) 30 (48.4%) 23 (38.3%) 7 (16.7%) 2 (13.3%) 89 (34.1%)
pack-years mean (s.d.) 3.9 (5.4) 7.5 (10.5) 12.9 (17.3) 21.3 (22.9) 20.9 (23.5) 16.4 (27.4) 14.4 (19.6)
under 10 pack-years n (%) 6 (42.9%) 10 (14.7%) 14 (22.6%) 8 (13.3%) 9 (21.4%) 4 (26.7%) 51 (19.5%)
10-29.9 pack-years n (%) 2 (14.3%) 20 (29.4%) 17 (27.4%) 15 (25.0%) 4 (9.5%) 2 (13.3%) 60 (23.0%)
30 pack-years or more n (%) 0 (0.0%) 4 (5.9%) 9 (14.5%) 20 (33.3%) 16 (38.1%) 3 (20.0%) 52 (19.9%)
Age group
4.3.2 Definition of healthy and asymptomatic subjects
Based on the structured interview, previous medical conditions and prevailing symptoms
were assessed to determine a subgroup of healthy asymptomatic adults. Based on the
questionnaire, individuals were considered healthy and asymptomatic if they gave no
positive answers to over 50 questions dealing with symptoms, diagnosed respiratory
diseases, and use of pulmonary medications. Respiratory symptoms evaluated included
wheezing, attacks of shortness of breath, sputum production, dyspnea, and dyspnea on
exertion. Questions on respiratory symptoms used to identify study subjects who were not
healthy and asymptomatic are listed in Table 4.
In addition to these questions, subjects reporting having a previous diagnosis of
asthma, COPD, emphysema, chronic bronchitis, or any other major respiratory or medical
condition were also excluded. The open question of “do you have any other pulmonary
disease not listed here” was also evaluated on an individual basis. Uncomplicated
hypertension and obesity as such were not considered significant if the subject did not
report any of the aforementioned respiratory symptoms.
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Table 4. Questions on respiratory symptoms used to define healthy and asymptomatic subjects
Healthy: subject excluded if meeting any one of these criteria (answer in parentheses)
Q16: Do you usually have phlegm when coughing or hawking, or do you have phlegm in your chest
which is difficult to bring up most days in periods of (at least 3 months/year, during two
successive years)?
Q19: Do you usually have wheezing, whistling, or a noisy sound in your chest when breathing? (yes)
Q21: Have you had wheezing or whistling in your chest at any time in the last 12 months? (yes)
and Q22: Have you been at all breathless when the wheezing noise was present? (yes)
and Q23: Have you had this wheezing or whistling when you did not have a cold? (yes)
Q33: Do you have to stop for breath when you walk at your own pace on level ground? (yes)
Q39: Have you had attacks of shortness of breath with wheezing or whistling in the last 12 months?
(yes)
Q42: Has this happened in the last 12 months? (yes)
(refers to Q41: have you ever been woken at night or early in the morning by an attack of
shortness of breath with wheezing or whistling?)
Asymptomatic: subject excluded if meeting any one of these criteria (answer in parentheses)
Q08: Have you had long-standing cough during the last years? (yes)
Q10: Do you have this kind of cough most days a week in periods of more than two weeks? (yes)
Q12: Do you have this cough most days a week in periods of more than two weeks? (yes)
Q14: Do you usually bring up phlegm from your chest when coughing or hawking? (often)
Q15: Have you noticed phlegm in your chest which is difficult to bring up? (yes)
Q21: Have you had wheezing or whistling in your chest at any time in the last 12 months? (yes)
Q36: Have you had any attacks of shortness of breath or breathlessness in the last 12 months? (yes)
Q48-Q66 (except Q65): Factors that provoke wheezing or whistling, or attacks of shortness of breath,
with or without cough:  (3 or more “yes” answers)
Factors including: furred animals, pollen, mold, smoke, dusty places, strong-smelling scents, car
exhausts, air pollution, airway infections, medicines, food, psychological factors, cold air,
physical exercise, occupational setting.
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4.4 Statistical methods
Statistical analyses were performed with the Statistical Package for Social Sciences (SPSS
for Windows, version 15.01; SPSS, Chicago, IL, USA), with the exception of the 95%
confidence intervals for the 95th percentile values, which were calculated with Confidence
Interval Analysis (CIA, version 2.1.2; Trevor Bryant, University of Southampton,
Southampton, UK). Chi-square and Fisher’s exact tests were used to analyze differences
between groups. Normality of continuous variables was checked by the Kolmogorov-
Smirnov test. Logarithmic transformation of variable was done, if necessary to achieve
normality. Correlations were assessed with the Pearson correlation coefficient (r-value).
The variation of each variable in an individual (II) was assessed by its coefficient of
variation (CoV) and the intraclass correlation coefficient (ICC). The CoV for each
measurement was calculated by dividing the standard deviation of the three measurements
with their mean. The ICC is an application of analysis of variance that produces measures
of  consistency  or  agreement  of  values  within  cases  (Shrout  &  Fleiss,  1979;  McGraw  &
Wong, 1996). The ICC for measurements with three repetitions (II) is calculated with the
following formula:
ICC = (MSB-MSW)/(MSB+2*MSW) (1),
where MSB is mean squares between groups and MSW mean squares within a group. A
one-way random effects model was used for the ICC. The agreement between changes in
FVC and FEV6 in  response  to  bronchodilation  (IV)  was  also  assessed  with  ICC.  The
method described by Bland & Altman (1986) was used to demonstrate agreement between
repeated measurements (II) (Chinn, 1991).
The  effect  of  gender  on  bronchodilation  (III)  was  assessed  with  an  analysis  of
covariance (ANCOVA) model using height and baseline FEV1/FVC ratio as covariates.
Linear regression modeling was used to evaluate the role of different determinants in
bronchodilation response in the population.
P-values  of  less  than  0.05  were  considered  significant  for  all  analyses  other  than
correlations, for which a p-value of less than 0.01 was regarded as significant. Data are
presented as mean (SD) unless otherwise indicated in the text.
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5 Results
5.1 Forced expiratory time and its determinants
The average FET for the nonselected population sample was 10.7 (SD 4.3) s, and the
histogram distribution is shown in Figure 7. The mean FET was 11.3 (4.4) s for men and
10.3 (4.3) s for women. The difference between men and women was not significant
(p=0.265) when tested with ANCOVA using FEV1/FVC  ratio  as  a  covariate.  FET  was
over six seconds in 90.7% of men and 86.8% of women. In the population the upper 95th
percentile of spirometric FET was 18.2 s.
Figure 7 Distribution of forced expiratory time (FET) in a) men and b) women in the general
population
Distribution of FET in relation to age and BMI is presented in Figure 8. FET increased
with increasing age, with the greatest values in the age cohort of 50-59 years. BMI
correlated also significantly with FET (r=0.243, p<0.01). Baseline FEV1 and  FVC  had
little effect on FET itself, but airflow limitation assessed by the FEV1/FVC ratio showed a
significant  negative  correlation  with  FET.  The  distribution  of  FET  in  relation  to  FEV1,
FVC, and the ratio of FEV1/FVC are presented in Figure 9.
Previous smoking history in terms of pack-years smoked had a significant correlation
with FET (r = 0.297, p<0.01) and FEV1/FVC (r = -0.386, p<0.01). FET was slightly
shorter and more evenly dispersed in healthy asymptomatic nonsmokers with a mean of
9.8 (SD 3.9) s. The mean value in healthy men was 10.1 (3.7) s and in women 9.7 (4.2) s.
Also in healthy asymptomatic nonsmokers the FEV1/FVC ratio was the most important
determinant for FET (r= -0.491, p<0.01).
 a)   b)mean 11.3
SD 4.4
n= 248
mean 10.3
SD 4.3
n= 355
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Figure 8 Population distribution of forced expiratory time (FET) in relation to a) age and b)
BMI (adapted from study I with permission)
Figure 9 Distribution of forced expiratory time (FET) in the general population in relation to
a) baseline forced expiratory volume in one second (FEV1), b) baseline forced vital
capacity (FVC), and c) the ratio of FEV1/FVC at the baseline (adapted from study I
with permission)
a) b)
a) b)
c)
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5.2 Intrasession repeatability of spirometry
The intrasession repeatability was analyzed from the three acceptable prebronchodilation
spirometry maneuvers for the population sample. The stricter quality criteria reduced the
sample to 603 subjects, 248 men and 355 women. Repeatability was assessed in terms of
the difference between the two largest FEV1, PEF, FEV6, and FVC values. FET values
corresponding to the two best curves were selected, with the best curve defined as the
greatest sum of FEV1 and FVC. In addition, the coefficients of variation (CoV) and
intraclass correlation coefficients (ICCs) were calculated.
In  terms  of  absolute  and  relative  difference,  FEV1, FEV6, and FVC were equally
repeatable with mean differences around 45 ml and 1.3%. The difference of FET was on
average -0.0 s or -2.0%, with the best curves having slightly shorter FET compared to next
best curves resulting in negative average changes.
The mean CoV was 1.4% for FVC, FEV6, and FEV1, but for FET it was 11.3%. The
ICC for FET was 0.873, and for FVC, FEV6, and FEV1 0.996. The upper 95th percentile
of difference between the FET corresponding to the best and second-best curves was 2.7 s
and 23.7% of the best-curve FET. Figure 10 presents a modified Bland-Altman plot
showing the difference between the values of two best curves FET is plotted against the
average of these two values.
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Figure 10 A modified Bland-Altman plot of the intrasession repeatability of forced expiratory
time (FET)(Reprinted from study II with permission)
Repeatability of FET measured in terms of CoV did not differ significantly between
men and women. Of the subjects, 11.6% had best-curve FET of < 6 s. The distribution of
the CoV as a function of age and baseline lung function measures of FEV1,  FVC,  and
FEV1/FVC is shown in Figure 11. The CoV of FET was slightly larger for older
participants (r=0.109, p<0.01). Other anthropometric or spirometric variables including
FET itself had little effect. The exclusion of outliers had no significant effect.
53
Figure 11 Distribution of intrasession coefficient of variation (CoV) of forced expiratory time
(FET) in relation to a) age, b) body mass index (BMI), c) forced expiratory volume in
one second (FEV1),  d)  forced  vital  capacity  (FVC),  e)  FEV1/FVC, and f) maximum
mid-expiratory flow (MMEF)
a)   b)
c)   d)
e)    f)
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Variability of FEV6 in  terms  of  CoV  was  slightly  more  pronounced  in  older
individuals (r=0.261, p<0.01) and in those with low baseline FEV1 (r= -0.252, p<0.01) or
FVC (r= -0.237, p<0.01). Subjects with airflow limitation, measured in terms of reduced
FEV1/FVC ratio, had slightly smaller variability of FET (CoV 10.6% vs. 11.4%, ICC
0.897 vs. 0.840), but slightly higher variability of both FEV6 (1.5% vs.  1.3%)  and  FVC
(1.7% vs. 1.3%). The intrasession repeatability of FEV6 was slightly but not significantly
better than that of FVC for individuals with airflow limitation. The difference between the
largest FEV6 and FVC increased almost linearly with FET over 6 s.
5.3 Bronchodilation response
Of the original population sample (n=633), five subjects did not participate in the
bronchodilation testing, reducing the study sample to 628 subjects (368 women, 260 men).
5.3.1 FEV1 response to bronchodilation
Population sample
The  absolute  and  relative  changes  of  FEV1 after inhaled salbutamol with respect to
baseline spirometry are shown in Figure 12. Both absolute and relative change of FEV1
showed normal or near-normal distribution within the population. FEV1 increased on
average 77.2 (SD 109.7) ml or 2.5% (3.9%) of baseline FEV1.  A gender  difference  was
found, with an average change in FEV1 for men of +107.4 (130.6) ml or 3.0% (4.3%), and
for women +55.9 (86.1) ml or 2.2% (3.7%), but the gender difference was not significant
when tested with analysis of covariance using height and baseline FEV1/FVC ratio as
covariates. In 2.7% of both genders, FEV1 decreased more than 100 ml, and in 19.6% the
decrease was below 100 ml. PEF increased on average 1.8% (7.0%).
Baseline FEV1/FVC ratio was the strongest factor influencing change in FEV1 in the
population sample. The relationships between change in FEV1 and baseline FEV1, and the
ratio of FEV1/FVC are demonstrated graphically in Figure 13. No significant gender
difference was present in either absolute FEV1 response (p= 0.642) or relative change
(p=0.918) when adjusted for height and baseline FEV1/FVC ratio. Absolute change in
FEV1 slightly, but significantly, increased with increasing baseline FVC (p<0.01), but
relative change did not. The 95th percentile of change in FEV1 was 260 ml (95% CI 247-
311) and 8.5% (7.7-10.7) in the whole population.
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Figure 12 Histogram distribution of absolute change of FEV1 in the bronchodilation test in a)
men and b) women, and the change relative to baseline in FEV1 in c) men and d)
women..
Figure 13 Change of FEV1 in relation to a) baseline FEV1 and b) baseline FEV1/FVC-ratio in
the population (adapted from III with permission)
a)   b)
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The combined effects of different anthropometric and spirometric determinants on the
change in FEV1 were assessed with a linear regression model. Age, gender, and baseline
FVC were significant for absolute change, with age, gender, and baseline airflow
limitation were significant in the relative change model. However, the effect of
anthropometric variables, such as age and height, was too weak to have any clinical
significance, which can be verified from Figure 14.
Figure 14 Change of FEV1 in relation to a) age, and b) height in the population sample
Healthy asymptomatic nonsmokers
Among healthy asymptomatic nonsmokers (n=219), the mean absolute change of FEV1
was +62.0 (89.7) ml or +1.8% (2.6%); among men +97.6 (107.3) ml or 2.3% (2.6%) and
among women +43.1 (72.4) ml or 1.5% (2.6%). Greater than 100 ml reductions in FEV1
after bronchodilation were seen in 2.6% and 2.1% of healthy asymptomatic nonsmoking
men and women, respectively. Both absolute and relative change in FEV1 showed normal
or near-normal distribution. Overall, the 95th percentile  of  change  in  FEV1 was 240 ml
(95% CI 224-254) and 5.9% (5.6-7.7).
Height, baseline FVC, and age had the strongest independent effects on the absolute
change of FEV1, and FEV1/FVC-ratio and age on the relative change of FEV1 in healthy
asymptomatic nonsmokers. The effect of gender on the height and baseline FEV1/FVC
ratio-adjusted absolute (p=0.380) or relative FEV1 response (p=0.618) was not significant.
5.3.2 FEV6, FVC, and FET responses to bronchodilation
The absolute and relative changes of FVC and FET are shown in Figure 15. In the
bronchodilation test, 23.1% of men and 33.2% of women had greater than 2.5% reduction
in FVC. The mean change in FVC was -42.8 (122.4) ml or -1.0% (3.3%). The upper 95th
percentile for change in FVC was 137.0 ml and 4.0%. The mean change in FET was -0.2
(2.7) s or 0.4% (23.9%), with a 95th percentile of 3.4 s or 44.0%.
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Table 5. Change of FEV6, FVC, and FET during bronchodilation test in the general
population stratified by gender
mean (SD) 95% CI
95th
percentile mean (SD) 95% CI
95th
percentile
change of FEV1 [ml] 107.4 (130.6) 91.4 - 123.3 335.3 55.9 (86.2) 47.1 - 64.8 214.5 <0.001
change of FEV1 % from baseline 3.0 (4.3) 2.5 - 3.5 8.6 2.2 (3.7) 1.8 - 2.6 8.4 0.009
change of FEV6 [ml] -2.1 (137.7) -18.9 - 14.8 195.8 -21.4 (93.5) -31.0 - -11.8 144.9 0.036
change of FEV6 % from baseline 0.1 (3.5) -0.3 - 0.6 4.8 -0.5 (3.1) -0.8 - -0.2 5.1 0.023
change of FVC [ml] -35.6 (147.6) -53.6 - -17.6 170.2 -48.1 (100.9) -58.4 - -37.8 132.2 n.s.
change of FVC % from baseline -0.6 (3.4) -1.0 - -0.2 3.6 -1.2 (3.2) -1.6 - -0.9 4.4 0.016
change of FET [s] -0.1 (2.6) -0.5 - 0.2 3.2 -0.3 (2.7) -0.5 - 0.0 3.7 n.s.
change of FET % baseline -0.6 (21.2) -3.2 - 2.0 34.7 1.2 (25.6) -1.4 - 3.8 48.6 n.s.
Men (n=260) Gender
difference
(p-value)
Women (n=368)
Figure 15 Concurrent relative and absolute changes in FVC and FET in the bronchodilation
test with 0.4 mg salbutamol in the general population. The dotted lines represent 12%
and 200 ml from baseline changes for FVC and 3.0 s or 24% from baseline changes
for FET
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FEV6 also on average decreases, but the reduction is less marked than in FVC, with a
mean of -13.4 (114.2) ml or -0.2% (3.3%) and a 95th percentile of 169.0 ml and 5.0% from
baseline. The concurrent changes in FEV6, FVC, and FET in the bronchodilation test are
outlined in Table 6. The concurrent change in FEV6 and FVC are demonstrated in Figure
16. FEV6 decreased significantly more in women both in absolute and in relative
measures, whereas the gender difference was only significant in relative change in FVC.
Age, height, weight, or BMI did not correlate significantly with changes in FVC, FEV6, or
FET during the bronchodilation test.
Figure 16 Concurrent change in FVC and FEV6 in the bronchodilation test in the general
population. The dotted lines represent +12% from baseline and +200 ml limits
Four subjects (0.6% of population) had a change in FVC from baseline of 12% or
greater and at least 200 ml. Using the same threshold value, six subjects had a significant
change of FEV6. One individual had a significant increase in FVC, but an insignificant
increase in FEV6, and for her this increase in postbronchodilation FVC was caused by an
increase of FET of 8 s and 71% relative to baseline FET. This subject can easily be noted
from Figure 16. On the other hand, two subjects had a significant increase with FEV6 but
not with FVC, and both of them had a shorter FET in postbronchodilation spirometry.
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Figure 17 Change in FVC in relation to baseline FEV1/FVC ratio in the general population. The
dotted line shows FEV1/FVC=70% limit defined by the GOLD criteria
The relationship of change in FVC to postbronchodilation spirometry variables,
reflecting obstruction and its grade, is displayed in Figure 17. Volume bronchodilation
became increasingly common as the ratio of FEV1/FVC decreased.  The average change in
FVC was positive for subjects with baseline FEV1/FVC ratio <LLN.
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6 Discussion
6.1 Methodology
This study is a part of a larger FinEsS study on respiratory epidemiology. The study
methodology reflects the international cooperation and its challenges. The original
intention was that a uniform methodology be followed in the different centers to enable
international comparisons. For flow-volume spirometry, the ATS 1994 Update of the
Spirometry  Standard  was  chosen.  However,  national  differences  still  prevailed;  for
example, in Helsinki, the spirometry repeatability criteria were based on ERS 1993
criteria, possibly because they were considered to be more stringent. In bronchodilation
testing,  the  dose  of  salbutamol  differed  between the  centers,  with  Swedish  centers  using
800 µg of salbutamol. Also posture varied, with spirometry conducted seated in Finland,
but standing in Sweden. This made it impossible to compare spirometry data between
centers. It would have been much easier had the ATS 1994 criteria been uniformly
followed, although some of these considerations, such as posture, were not unambiguously
stated in the standard.
Much discussion has been held on the methodology of FET measurements and patient
instruction. The spirometry procedures followed regular specialist pulmonary function
testing practices. In Helsinki, all measurements were undertaken by two trained and
experienced technicians. Patients were vigorously coached to achieve a plateau and to
fulfill  end-of-test  criteria.  There  was  no  set  time  limit  after  which  patients  would  have
been less vigorously coached, but in reality the nurses likely tended to stop encouraging
patients at individually common practice levels. The nurses did not know in advance that
expiratory times would be evaluated, but they conducted the spirometry sessions
following regular practices. The findings therefore reflect the situation encountered in
normal  pulmonary  function  testing  and  are  not  a  result  of  specially  designed  FET
measurements. Our intention was not to evaluate FET as a diagnostic variable per se, but
we considered it a potentially relevant quality measurement early on in the analysis.
FET values were taken as measured by the computer software. In reality, the
expiratory time is usually longer since the computer software and sensor do not include
the end-expiratory plateau in the reported value.
This is a population study and the subjects represent a random population sample.
Subjects were instructed to continue their regular medication, with the exception of oral
antihistamines, which were discontinued for three to five days before the skin Prick-
testing. Short-acting ?-agonists were asked to be avoided 4 h and long-acting ?-agonists
for 12 h previous to testings, but failure to do so did not result in exclusion of the patient
from the study. Since patients with asthma continued their regular therapeutic medication,
the subjects with previously diagnosed asthma had very few positive responses in
bronchodilation testing. This should be taken into consideration in evaluating the results.
However, temporary discontinuation of anti-asthmatic medication was not deemed
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possible since corticosteroids should be discontinued for at least one month;
discontinuation of asthma medication would likely result in more symptomatic subjects.
Population studies should reflect actual situations in the population. Subjects with
irreversible airflow obstruction (reduced FEV1/FVC) could, however, show reversibility
following a trial of corticosteroids, and this cannot be reflected in a single cross-sectional
study.
6.2 Main results
6.2.1 Forced expiratory time in flow-volume spirometry
The earliest studies on FET have assessed the usability of auscultated FET as a simple
diagnostic test for detection of chronic obstruction (Rosenblatt & Stein, 1962; Lal et al.,
1964; Macdonald et al., 1975; Kern & Patel, 1991; Holleman et al., 1993). Auscultated
FET was found to be a clinically potentially relevant measure for the bedside diagnosis of
airflow obstruction when pulmonary function measurements were not readily available,
but  it  was  surpassed  by  the  ready  availability  of  peak  flow  meters  (PEF)  and  the  rapid
development of spirometers that became available for more accurate diagnosis in primary
care (Holleman et al., 1993). Spirometric FET has been studied surprisingly little.
Spirometry standards have previously taken FET into consideration only in evaluation of
sufficiently long exhalations during forced expiratory maneuvers and set a limit of 6 s for
minimum duration of the exhalation (Quanjer et al., 1993; ATS, 1995).
FET has been a measure of increasing interest as the joint ATS/ERS Task Force on
Interpretation of Spirometry stipulated that when only FVC increases significantly (>12%
and >200 ml) during bronchodilation testing it must be verified that this is not caused by
longer exhalations in postbronchodilator spirometry (Pellegrino et al., 2005).
In previous studies, FET has been shown to be prolonged in conditions causing airflow
limitation and obstruction (Kern & Patel, 1991, 1994; Vandevoorde et al., 2005). The
diagnostic utility with either auscultated or spirometric FET is very poor.
We have shown that FET is on average 10.7 s in standard flow-volume spirometry (I),
a value that is slightly larger than in previous reports on normal controls, being at
approximately the same level as in obstructed subjects (Hankinson et al., 1977;
Vandevoorde et al., 2005). Airflow limitation measured by reduced FEV1/FVC ratio was
the strongest determinant for FET, and differences in FET are inherently affected by the
prevalence of airflow limitation and age distribution in the subjects under investigation.
This is the first report on an unselected general adult population in an epidemiological
study. The lower values reported based on register data from tertiary care pulmonary
function laboratories might reflect a greater incidence of restrictive diseases in patient
samples than in our population sample.
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We have demonstrated that besides a reduced FEV1/FVC  ratio,  age  has  a  positive
correlation with FET. Also the difference between FVC and FEV6 increases with age.
FEV1/FVC is known to diminish during normal aging. The significance of reduced
FEV1/FVC in asymptomatic older adults is controversial. Mannino and coworkers (2003,
2006) have shown that reduced FEV1/FVC<70% while FEV1/FVC is still above the lower
limits of normal reference values is associated with greater morbidity and mortality. In a
separate report, FEV1 in itself was found to be a predictor of greater mortality of all causes
(Knuiman et al., 1999; Schünemann et al., 2000). In the older age cohorts, history of
childhood infections, accumulated smoking pack-years, and prevalence of disease are also
greater confounding variables.
In  this  study,  FET  was  shown  to  be  less  repeatable  than  the  main  parameters  from
flow-volume spirometry. This is in line with previous literature. Cochrane et al. (1977)
and recently Tsai et al. (2006) have reported coefficients of variation for FET around 11-
14%, which are larger than for any other flow-volume spirometry variable. This is the first
population study on FET and the first study to report changes in FET during
bronchodilation testing. A prolongation of FET of 3 s is suggested to be considered
excessive based on the intrasession repeatability (I).
In  bronchodilation  testing  (IV),  FET  was  shown  to  seldom  increase  —  only  one
subject had an increase of FET of over 3 s. Since FET varies more than other spirometry
variables, it should be measured from the same curve as the FVC during bronchodilation
testing.
6.2.2 FEV1 response to bronchodilation in the general population
In bronchodilation testing, FEV1 increased in the population 2.5% from baseline –
3.0% in men and 2.2% in women. This is in line with earlier Nordic studies (Johannessen
et al, 2005, 2006; Lehmann et al., 2006, 2007) and population studies elsewhere (Dales et
al., 1988). Airflow limitation (reduced FEV1/FVC) in baseline spirometry was found to be
the strongest determinant of change in FEV1. Greater lung volumes, namely FVC and
FEV1 levels, were also associated with slightly larger changes in FEV1. Men had
somewhat larger responses than women, but the difference was partially caused by a
greater prevalence of airflow limitation and greater height and FVC in men. When these
confounding variables were controlled, the gender difference was not statistically
significant. Older subjects had slightly lower changes in FEV1, which have been attributed
to fatigue during testing, possible differences in ?-receptor levels on bronchial smooth
muscle, and smaller FVC, FEV1, and particularly FEV1/FVC. The age-related reduction in
change in FEV1 can also be slightly affected by the smaller prevalence of asthma in older
age cohorts.
Despite the multitude of studies on bronchodilation and methodology, there is a
surprising scarcity of unselected population materials in this field. We show that negative
changes in bronchodilation testing are common, a phenomenon often discarded as outliers
or poor quality. In this study (III), we have demonstrated that FEV1 bronchodilation is
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significant at a lower level than previously thought, around 9% from baseline. The current
standard sets the limit at 12% of baseline and 200 ml. There were, however, a number of
potential confounders in this study. Subjects continued their regular medication, which
means that asthmatics usually received adequate treatment, and hence, reversible airflow
limitation was seen less often. In addition, spirometry maneuvers affect the results. During
spirometry, inspiratory spirometry was regularly measured in all individuals. Women and
older subjects possibly had less bronchodilation responses since they potentially could
have more fatigue during testing.
Bronchodilation response was shown to be slightly dependent on age, gender, and
baseline airflow limitation (III).
6.2.3 FEV6 and FVC response to bronchodilation in the general population
Determination of FVC bronchodilation response with flow volume spirometry is
challenging. Changes in FVC only indirectly reflect changes in lung compartments, e.g.
RV. The FVC maneuver can be physically demanding for subjects with airflow limitation.
Previous studies have reported contradictory results in the necessity of body
pletysmography in detecting volume responders. FVC is known to be dependent on
expiratory time (Glindmeyer et al., 1987) especially in subjects with airflow limitation,
which  was  also  verified  in  our  studies  (I,  II,  IV).  Moreover,  we  have  shown  that  the
difference between FVC and FEV6 increases  as  FET increases  and  also  during  aging  (I,
II).
The “new” requirement in the ATS/ERS 2005 standard of consideration of FET when
only FVC increases in bronchodilation testing follows reports on severely obstructed
subjects and patients with emphysema (Cerveri et al., 2000; Newton et al., 2000;
O’Donnell et al., 2001). Bronchodilation response tends to initially be in terms of flow
(measured  with  FEV1) when airflow limitation is mild, but with worsening severity of
obstruction the bronchodilation response is more often detected in terms of volume
(measured with FVC) (Cerveri et al., 2000; Newton et al., 2000; O’Donnell et al., 2001;
Schermer et al., 2007; Tashkin et al., 2008).
In Study II,  we observed that FEV6 is as repeatable as FVC in the population and in
subjects with FEV1/FVC<LLN, in fact showing slightly better reproducibility for FEV6
than for FVC. This is most likely due to prolonged FET in obstructed subjects and greater
variation in FET. In Study IV, FEV6 was shown to differentiate positive responders even
more reliably than FVC since it recognized the one case where the increase in FVC was
due to longer FET in postbronchodilation spirometry. This increase in FVC due to longer
exhalation in postbronchodilation spirometry could be recognized only with the
consideration of change in FET or FEV6. “Isolated volume bronchodilation” is rare in the
population; in our sample, true FVC bronchodilation in the absence of FEV1
bronchodilation and without increases in FET was not found. One subject had an increase
in FVC due to prolongated FET. The limit for significant change in FEV6 in
bronchodilation  test  is  suggested  to  be  around  6%,  which  is  below  the  documented
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repeatability of FEV6. The use of FEV6 would eliminate the need for controlling
exhalation times and would identify volume responders without prolonged FET. Change
in FEV6 also identified those two subjects whose change in FVC fell below significant
levels due to shorter postbronchodilator FET (IV).
Decreases in both FVC and FEV6 during the bronchodilation test were surprisingly
common. The trend towards negative changes in FVC has been reported earlier
(Johanessen et al., 2006), but is largely unrecognized. In some studies, negative changes in
bronchodilation testing have been considered the result of technical flaws (Goedhart et al.,
2004). Since neither the expiratory time, extrapolated volume, or peak expiratory flow
changed, it indicates that the expirations had equally forceful beginnings and continued
efforts,  i.e.  the  maneuvers  do  not  seem  to  be  prematurely  terminated.  Negative  changes
might be caused by increased collapsibility as a result of reduced airway smooth muscle
tone with ?2-agonists or by increased physiological airway collapsibility in healthy adults.
On the contrary, those subjects with clearly reduced FEV1/FVC-ratio indicating bronchial
obstruction showed increased FVC after bronchodilation (IV).
Prolongation of expiratory maneuvers during bronchodilation testing has been
proposed to reflect a form of bronchodilation itself (de la Hoz, 2002; Newton et al., 2002;
Tsai et al., 2006). The possibility of prolonged FET representing a form of
bronchodilation warrants further consideration, but this cannot be analyzed from our data.
The so-called “volume bronchodilation” is controversial in flow-volume spirometry, with
many authors feeling a need to use pletysmography to identify volume response. Smith
and coworkers (1992) found that FEF25-75% were higher at baseline spirometry in
subjects who required pletysmography to identify bronchodilation response. Light and
coworkers, by contrast, observed pletysmography to yield no benefit in the assessment of
volume response. The significant limit of bronchodilation responses and the repeatability
of pletysmography are less well documented. Furthermore, pletysmography is not widely
available, whereas flow-volume spirometry is a fundamental diagnostic procedure.
In our population sample, FEV6 performed even better than FVC in the
bronchodilation test. Possibly, FEV6 could also identify reversibility caused by early small
airways obstruction. The use of flow values reflecting small airways dysfunction, namely
MEF50 and MMEF, has been hindered by great intrasession and short-term variability and
dependence of instantaneous flow values on the lung volume at which they are measured.
This is particularly problematic during bronchodilation testing, when FVC can both
increase and decrease significantly. FEV6 is the cumulative volume of air expelled during
the first 6 s of a forced expiratory maneuver starting from a back-extrapolated time zero.
In early airflow limitation in small airways in the early stages of COPD, the FET is not yet
markedly prolonged and changes in small airways are most likely also reflected in changes
in FEV6. In moderate to severe COPD, airflow limitation is more prominent in large
airways, but in this subgroup volume and expiratory time changes are more likely.
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7 Conclusions
1. FET was around 10 s in the general population and in healthy nonsmokers, but
longer in subjects with airflow limitation and in the elderly (I).
2. FEV1, FEV6, and FVC are equally repeatable within a session, but FET varies
considerably more. Anthropometric and spirometric variables, including FET,
had little effect on repeatability. A change of 3 s in FET was considered
significant (II). FEV6 was  equally  repeatable  also  in  subjects  with  airflow
limitation.
3. FEV1 response  to  bronchodilation  was  significant  around  9%  from  baseline  in
the population sample and around 6% from baseline in healthy nonsmokers.
Age, gender, and baseline FVC were the most significant determinants (III).
4. FVC, FEV6, and FET in general decreased in the bronchodilation test. A
significant increase of FEV6 to  bronchodilation  was  around  6%  from  the
baseline.  The  most  significant  determinant  for  FEV6 response was baseline
FEV1/FVC. FVC response caused by longer exhalation was detected with flow-
volume spirometry using FEV6, which proved to be also a suitable surrogate
measure of FVC reversibility. The use of FEV6 in lieu of FVC removes the need
to control expiratory time. Therefore it might be useful especially in the primary
care (IV).
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Appendix 1
FinEsS tutkimus The FinEsS Study
Hengityssairauksien haastattelu Respiratory questionnaire
Helsinki
1. Syntymäaika Date of birth
2. FinEsS numero FinEsS number
3. Rotu Ethnic origin: valkoinen rotu Caucasian; musta rotu Negroid; keltainen rotu
Oriental; muu Other
4. Sukupuoli Gender: mies male; nainen female
5. Otos Sample
6. Koodit Coding: country; center; area; nationality [not used in Helsinki]
7. Väestötiheyden luokitus (ei käytössä Helsingissä) Population density category (not used
in Helsinki)
Yskä ja limannousu Cough and phlegm
8. Onko Sinulla ollut viime vuosina pitkäaikaista yskää? Have you had long-standing
cough during the last years? ei no; kyllä yes
9. Yskitkö tai köhitkö yleensä aamuisin? Do you usually cough in the morning? ei no;
kyllä yes
vastaa kysymykseen 10 vain jos vastasit kyllä kysymykseen 9. If you answered YES to
question 9, please answer question 10:
10. Onko Sinulla tällaista yskää tai köhää aamuisin useimpina viikon päivinä yli kahden
viikon jaksoissa? Do you have this cough most days a week in periods of more than
two weeks? ei no; kyllä yes
11. Yskitkö tai köhitkö muuhun aikaan päivästä tai öisin? Do you usually cough during
other times of the day, or at night? ei no; kyllä yes
vastaa kysymykseen 12 vain jos vastasit kyllä kysymykseen 11. If you answered YES to
question 11, please answer question 12:
12. Onko sinulla tällaista yskää tai köhää useimpina viikon päivinä yli kahden viikon
jaksoissa? Do you have this cough most days a week over periods of more than two
weeks? ei no; kyllä yes
vastaa kysymykseen 13 vain jos vastasit kyllä kysymykseen 10 tai 12: If you answered
YES to question 10 or 12, please answer question 13:
13. Onko Sinulla tällaista yskää… Do you have this cough… harvakseen silloin tällöin?
sparsely now and then?; yleensä/tavallisesti talvella? generally/commonly in winter?;
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pitkin vuotta jaksoittain tai kaikkina päivinä? intermittently or continuously
throughout the year?
14. Nouseeko yskiessä tai köhiessä keuhkoistasi yleensä limaa? Do you usually bring up
phlegm from your chest when coughing or hawking? ei no; silloin tällöin now and
then; usein often
15. Onko Sinulla keuhkoissa limaa, jota on vaikea saada irtoamaan? Do you have phlegm
on your chest that is difficult to bring up? ei no; kyllä yes
16. Esiintyykö Sinulla yskäjaksoja, jolloin useimpina päivinä yskiessä tai köhiessä
keuhkoistasi yleensä nousee limaa tai onko keuhkoissa limaa, jota on vaikea saada
irtoamaan? Do you usually have phlegm when coughing or hawking, or do you have
phlegm on your chest that is difficult to bring up most days in periods of ? ei, tai
<3kk/vuosi no, or <3 months; vähintäin 3kk/vuosi at least 3 months/year; kahtena
peräkkäisenä vuonna vähintäin 3kk/vuosi at least 3 months/year, over 2 successive
years
vastaa kysymykseen 17 vain jos rastitit kysymyksen 16 viimeisen vaihtoehdon: If you
answered YES to alternative three of question 16, please answer question 17:
17. Kuinka monen vuoden ajan? For how many years? ___ vuotta years
vastaa kysymykseen 18 vain jos rastitit kysymyksen 16 ensimmäisen vaihtoehdon: If you
answered NO to alternative three of  question 16, please answer question 18:
18. Onko Sinulla koskaan ollut pitkäaikaista yskää tai limannousua keuhkoista
pitkäkestoisina jaksoina? Have you ever had long-standing cough or long-standing
periods with phlegm in your chest? ei no; kyllä yes
Hengityksen vinkunat Wheezing and whistling
19. Esiintyykö Sinulla ajoittain vinkuvaa tai muutoin poikkeavan äänekästä hengitystä?
Do you sometimes have wheezing, whistling, or otherwise unusually noisy breathing?
ei no; kyllä yes
20. Oletko koskaan havainnut hengityksesi vinkuvan (keuhkoissa)? Have you ever noted
wheezing or whistling in your chest? ei no; kyllä yes
21. Onko Sinulla ollut hengityksen vinkunaa kertaakaan viimeisten 12 kuukauden aikana?
Have you had wheezing or whistling in your chest at any time in the last 12 months?
ei no; kyllä yes
vastaa kysymyksiin 22-24 (25) vain jos vastasit kyllä kysymykseen 21 If you answered
YES to question 21, please answer questions 22-24 (25):
22. Onko Sinulla ollut vähäisintäkään hengenahdistusta vinkunan yhteydessä? Have you
been at all breathless when the wheezing noise was present? ei no; kyllä yes
23. Onko Sinulla ollut hengityksen vinkunaa silloinkin kun et ole ollut flunssainen? Have
you had this wheezing or whistling when you did not have a cold? ei no; kyllä yes
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24. Onko hengityksesi vinkuvaa tai poikkeavan äänekästä viikon useimpina päivinä? Do
you have wheezing, whistling, or a unusually noisy breathing most days of the week?
ei no; vain jaksoittain yes, but only periodically; kyllä, pitkin vuotta yes, throughout
the year
mikäli vastasit: JAKSOITTAIN kysymykseen 24, merkitse minkä kuukausien aikana If
you answered PERIODICALLY to question 24, please list the months:
25. Kuukaudet jolloin hengityksen vinkunoita esiintyy The months in which wheezing or
whistling was present:
Hengenahdistus yleensä Breathlessness in general
26. Onko Sinulla liikuntavaikeuksia muusta syystä kuin keuhko- tai sydänsairauden
vuoksi? Are you disabled for any reason other than heart or lung trouble? ei no/not
applicable; kyllä yes
vastaa kysymykseen 27 vain jos vastasit kyllä kysymykseen 26 If you answered YES to
question 26, please answer question 27:
27. Mistä syystä? For what reason? aivoverenkiertosairaus cerebrovascular disease;
lihassairaus myopathy; raajojen liikkuvuus rajoittunut limited movement of the
extremities; muut syyt other
28. Oletko pyörätuolin käyttäjä? Do you use a wheelchair? ei no; kyllä yes
29. Esiintyykö Sinulla koskaan hengenahdistusta tai hengitysvaikeutta? Do you ever have
trouble breathing? ei, no; kyllä yes
vastaa kysymykseen 30 vain jos vastasit kyllä kysymykseen 29 If you answered YES to
question 29, please answer question 30:
30. Esiintyykö Sinulla tällaista hengenahdistusta tai hengitysvaikeutta? Do you have this
trouble: jatkuvasti, hengitys ei koskaan ole täysin kunnossa continuously, your
breathing is never completely normal; toistuvasti, mutta hengitys palautuu aina
tavalliseksi repeatedly, but your breathing always gets returns to normal; vain
harvoin only rarely
31. Esiintyykö Sinulla hengenahdistusta tai hengitysvaikeutta kiirehtiessäsi tasamaalla tai
kun kävelet ylös loivaa mäkeä tai noustessasi rappuja yhden kerrosvälin omalla
vauhdillasi? Are you troubled by shortness of breath when hurrying on level ground
or walking up a slight hill or one flight of stairs at your normal pace? ei no; kyllä yes
vastaa kysymyksiin 32-34 vain jos vastasit kyllä kysymykseen 31 If you answered YES to
question 31, please answer questions 32-34:
32. Hengästytkö, kun kävelet tasamaalla ikäistesi henkilöiden kanssa? Do you get short of
breath when you walk with other people of your own age on level ground? ei no;
kyllä yes
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33. Joudutko pysähtymään hengähtääksesi välillä kun kävelet omalla vauhdillasi
tasamaalla? Do you have to stop for breath when you walk at your own pace on level
ground? ei no; kyllä yes
34. Hengästytkö pukeutuessasi tai riisuutuessasi? Do you get short of breath when
dressing or undressing? ei no; kyllä yes
Kohtauksittainen hengenahdistus ja ahtauden tuntu hengityksessä Attacks of
shortness of breath or chest tightness
35. Onko Sinulla koskaan ollut hengenahdistuskohtauksia tai ajoittain esiintyvää
poikkeavan tuntuista hengästymistä? Have you ever had attacks of shortness of
breath or periodically occurring breathlessness? ei no; kyllä yes
36. Onko Sinulla ollut yhtään hengenahdistuskohtausta tai hengästymiskohtausta
viimeisten 12 kuukauden aikana? Have you had any attacks of shortness of breath or
breathlessness in the last 12 months? ei no; kyllä yes
vastaa kysymykseen 37 vain jos vastasit kyllä kysymykseen 35 tai 36 If you answered
YES to question 35 or 36, please answer question 37:
37. Onko hengityksesi normaalia hengenahdistuskohtausten välillä tai ennen kohtausten
alkua? Is your breathing ”normal” before attacks start or between attacks of
breathlessness? ei no; kyllä yes
38. Onko Sinulla ollut koskaan hengenahdistuskohtausta ja samanaikaisesti hengityksen
vinkunaa? Have you ever had any attacks of shortness of breath with wheezing or
whistling? ei no; kyllä yes
vastaa kysymykseen 39 ja 40 vain jos vastasit kyllä kysymykseen 38 If you answered
YES to question 38, please answer questions 39 and 40:
39. Onko Sinulla ollut hengenahdistuskohtausta ja samalla hengityksen vinkunaa
viimeisten 12 kuukauden aikana? Have you had attacks of shortness of breath with
wheezing or whistling in the last 12 months? ei no; kyllä yes
40. Minkä ikäisenä Sinulla oli ensimmäinen hengenahdistuskohtaus samalla esiintyneen
hengityksen vinkunan kanssa? How old were you when you had the first attack of
shortness of breath with wheezing or whistling?ikä age ___ v years
41. Oletko koskaan herännyt yöllä tai varhain aamulla hengenahdistuskohtauksen ja
samanaikaisen hengityksen vinkunan vuoksi? Have you ever been woken at night or
early in the morning by an attack of shortness of breath with wheezing or whistling?
ei no; kyllä yes
vastaa kysymykseen 42 vain jos vastasit kyllä kysymykseen 41 If you answered YES to
question 41, please answer question 42:
42. Onko näin käynyt viimeisten 12 kuukauden aikana? Has this happened in the last 12
months?: ei no; kyllä yes
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vastaa kysymykseen 43 vain jos vastasit kyllä kysymyksiin 36, 39 tai 42 If you answered
YES to question 36, 39, or 42, please answer question 43:
43. Kuinka monta hengenahdistuskohtausta, vinkunan kanssa tai ilman, Sinulla on ollut
viimeisten 12 kuukauden aikana? How many attacks of shortness of breath, with or
without wheezing, have you had in the last 12 months? a) ei yhtään none; b) ehkä
kerran maybe one; c) kahdesta viiteen kertaan two to five times; d) yli viisi kertaa,
mutta ei useimpina kuukausina more then five times but not most months; e)
useimpina kuukausina mutta ei useimpina viikkoina most months, but not most weeks;
f) useimpina viikkoina mutta ei useimpina päivinä most weeks, but not most days; g)
useimpina päivinä most days; h) jaksoittain useimpina viikkoina periodically, most
weeks; i) jaksoittain useimpina päivinä periodically, most days
44. Onko Sinulla koskaan ollut ahtauden tunnetta rinnassa? Have you ever had a feeling of
tightness in your chest? ei no; kyllä yes
vastaa kysymykseen 45 vain jos vastasit kyllä kysymykseen 44 If you answered YES to
question 44, please answer question 45:
45. Onko tällaista tuntemusta ollut viimeisten 12kk aikana? Has this happened in the last
12 months? ei no; kyllä yes
46. Oletko koskaan herätessäsi kokenut ahtauden tunnetta rinnassa? Have you ever woken
with a feeling of tightness in your chest? ei no; kyllä yes
vastaa kysymykseen 47 vai jos vastasit kyllä kysymykseen 46 If you answered YES to
question 46, please answer question 47:
47. Onko näin käynyt viimeisten 12kk aikana? Has this happened in the last 12 months?
ei no; kyllä yes
Tekijöitä, jotka aiheuttavat Sinulle hengityksen vinkunaa tai hengenahdistus-
kohtauksia, yskän kera tai ilman yskää Factors provoking wheezing or whistling, or
attacks of shortness of breath, with or without cough
48. Karvaiset eläimet Furred animals, esim.: koira, kissa, lehmä, hevonen, kani jne
examples: dog, cat, cow, horse, rabbit, etc.: ei no; kyllä yes
49. Siitepölyaltistus Pollen exposure, esim.: lehdet, ruoho, ulkokukat examples: leaves,
grass, outdoor flowers: ei no; kyllä yes
50. Homeen haju tai homealtistus Smell of mold or mold exposure: ei no; kyllä yes
51. Tupakan savu tai haju Smoke or smell of tobacco: ei no; kyllä yes
52. Pölyisissä olosuhteissa yleensä Dusty places in general: ei no; kyllä yes
53. Voimakkaat tuoksut tai hajut Strong smelling scents (deodorantit, mausteet,
painomuste, savukaasut, puhdistusaineet, kukkien tuoksut jne deodorants, spices,
printing ink, fumes, cleaners, flowers, etc.): ei no; kyllä yes
54. Autojen pakokaasut Car exhaust: ei no; kyllä yes
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55. Muut ilmansaasteet Air pollution, other than car exhaust: ei no; kyllä yes
56. Hengitystieinfektiot, nuhakuumeet Airway infections, colds: ei no; kyllä yes
57. Lääkkeet Medicines: ei no; kyllä yes
jos kyllä, mitkä lääkkeet? if YES, which medicines?______
58. Ruoka Food, esim.: kala, äyriäiset, pähkinät, siemenhedelmät Examples: fish,
shellfish, nuts, seeded fruits: ei no; kyllä yes
Jos kyllä, mikä ruoka? If YES, which foods? ____________
59. Psyykkiset tekijät tai stressi Psychological factors or stress? ei no; kyllä yes
60. Kylmä ilma Cold air? ei no; kyllä yes
61. Muu säätila kuten kostea ilma, tuulinen, sumuinen tai lämmin ilma Other weather
conditions such as damp, windy, foggy, or warm weather? ei no; kyllä yes
62. Tuleeko Sinulle fyysisen rasituksen jälkeen välittömästi tai muutaman minuutin
kuluttua hengenahdistusta ja hengityksen vinkunaa? Do you get shortness of breath
with wheezing immediately or some minutes after physical effort? ei no; kyllä yes
63. Tuleeko Sinulle fyysisen rasituksen aikana hengenahditusta ja hengityksen vinkunaa?
Do you get shortness of breath with wheezing during physical effort? ei no; kyllä yes
64. Onko Sinulla ollut koskaan hengenahdistuskohtauksia ja hengityksen vinkunoita tai
astman oireita työpaikallasi? Have you ever had attacks of shortness of breath with
wheezing or whistling or symptoms of asthma at your workplace? ei no; kyllä yes
vastaa kysymykseen 65 vain jos vastasit kyllä kysymykseen 64  If you answered YES to
question 64, please answer question 65:
65. Onko näin käynyt viimeisten 12kk aikana? Has this happened in the last 12 months?
ei no;kyllä yes
66. Saatko hengenahdistusta ja hengityksen vinkunaa muista syistä kuin yllä mainittu? Do
you get shortness of breath with wheezing due to causes other than those specified
above? ei no; kyllä yes
jos kyllä; täsmennä: If YES:specify: _____
Astma ja krooninen keuhkoputken tulehdus (krooninen bronkiitti) Asthma and
chronic bronchitis
67. Onko Sinulla koskaan ollut astmaa? Have you ever had asthma? ei no; kyllä yes; en
tiedä don’t know
68. Onko lääkäri todennut Sinulla olevan astmaa? Have you been diagnosed as having
asthma by a doctor? ei no; kyllä yes; en tiedä don’t know
69. Onko Sinulla esiintynyt astmaa lapsuuden aikana tai hengityksen vinkunoita
varhaisessa lapsuudessa? Have you had wheezing or whistling in your chest in early
childhood or asthma during childhood? ei no; kyllä yes; en tiedä don’t know
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70. Käytätkö tai oletko aiemmin käyttänyt astmalääkkeitä säännöllisesti tai tarvittaessa?
Do you currently use or have you earlier used asthma medicine regularly or as
needed? ei no; kyllä yes
71. Onko lääkäri määrännyt Sinulle mitään astmalääkettä? Have you been prescribed any
asthma medicines by a doctor? ei no; kyllä yes
vastaa kysymyksiin 72-76 vain jos vastasit kyllä johonkin kysymyksistä 67-71 If you
answered YES to any of questions 67-71, please answer questions 72-76:
72. Minkä ikäinen olit kun lääkäri kertoi Sinulla olevan astmaa tai määräsi sinulle
astmalääkettä? How old were you when a doctor told you that you had asthma or
prescribed asthma medicine for you? Ikä Age ___ v years
73. Minkä ikäinen olit kun Sinulla oli ensimmäinen astmakohtaus tai astmaan liittyvä
tapahtuma tai oireinen astmajakso? How old were you when you had your first attack
of asthma or episode or period with asthma or symptoms of asthma? Ikä Age ___ v
years
74. Minkä ikäinen olit kun Sinulla oli viimeisin astmakohtaus? How old were you when
you had your most recent attack of asthma or symptoms of asthma? Ikä Age ___ v
years
75. Onko Sinulla ollut ylipäänsä mitään astmaoireita viimeisten 12 kuukauden aikana?
Have you had any symptoms of asthma during the last 12 months? ei no; kyllä yes
76. Oletko käyttänyt mitään astmalääkkeitä viimeisten 12 kuukauden aikana? Have you
used any asthma medicines in the last 12 months? ei no; kyllä yes
77. Onko lääkäri todennut Sinulla olevan kroonista keuhkoputken tulehdusta tai keuhkon
laajentumaa? Have you been diagnosed as having chronic bronchitis or emphysema
by a doctor?: ei no; kyllä yes; en tiedä don’t know
78. Mikä on oma käsityksesi, onko Sinulla kroonista keuhkoputken tulehdusta? In your
opinion, do you have chronic bronchitis? ei no; kyllä yes; en tiedä don’t know
79. Mikä on oma käsityksesi, onko Sinulla keuhkon laajentumatautia? In your opinion, do
you have emphysema? ei no; kyllä yes; en tiedä don’t know
jos kyllä vastauksia kysymyksissä 76-79, täsmennä kysymykset 80-93, mikäli olet
käyttänyt jotain kyseessä olevaa lääkettä hengityssairauden vuoksi viimeisten
12kk aikana If you answered YES to questions 76-79, please answer questions 80-
93 if you have used any of the medicines in question for respiratory disease during
the last 12 months:
80. Hengitettävää, avaavaa (lyhytvaikutteista ?2-agonistit) lääkettä? Inhaled short-acting
?2-agonists? ei no;silloin tällöin now and then; useampina päivinä viikossa most days
a week
vastaa myös kysymykseen 81, jos edellisessä muu kuin ei vaihtoehto If you answered now
and then or most days a week, please answer question 81:
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81. Milloin aloitit hengitettävän lyhytvaikutteisen avaavan (?2-agonistit) lääkkeen käytön?
When did you start using inhaled short-acting ?2-agonists?alle 1v sitten less than 1
year ago; 1-5 vuotta sitten 1-5 years ago; yli 5 vuotta sitten more than 5 years ago
82. Hengitettävää kortisonivalmistetta? Inhaled corticosteroids? ei no; silloin tällöin now
and then; useimpina päivinä viikossa most days a week
vastaa kysymyksiin 83 ja 84, jos edellä kysymyksessä 82 vastasit: silloin tällöin tai
useimpina päivinä viikossa If you answered now and then or most days a week,
please answer questions 83 and 84:
83. Milloin aloitit hengitettävän kortisonivalmisteen käytön? When did you start using
inhaled corticosteroids? alle 1 vuosi sitten less than 1 year ago;1-5 vuotta sitten 1-5
years ago; yli 5 vuotta sitten more than 5 years ago
84. Mikä on nykyinen annos? What is your current dose? <200µg/vrk, 200-800µg/vrk,
>800µg/vrk [vrk=day]
85. Antikolinergistä lääkettä? Anticholinergics? ei no; silloin tällöin now and then;
useimpina päivinä viikossa most days a week
86. Kromoglikaatteja tai nedokromiilia? Chromoglycates or nedochromile? ei no; silloin
tällöin now and then; useimpina päivinä viikossa most days per week
87. Hengitettävää pitkävaikutteista avaavaa (?2-agonistit) lääkettä? Inhaled long-acting
?2-agonists? ei no;silloin tällöin now and then; useimpina päivinä viikossa most days
a week
88. Avaavaa lääkettä (?2-agonistit) tablettimuodossa? Peroral ?2-agonists? ei no; silloin
tällöin now and then; useimpina päivinä viikossa most days a week
89. Teofylliinivalmistetta? Methylxanthines?ei no; silloin tällöin now and then; useimpina
päivinä viikossa most days a week
90. Avaavaa lääkettä sumuttimella (spiralla tms.)? Bronchodilating liquids via nebulizer?
ei no; silloin tällöin now and then; useimpina päivinä viikossa most days a week
91. Kortisonivalmistetta tablettimuodossa? Peroral corticosteroids? ei no; silloin tällöin
now and then; useimpina päivinä viikossa most days a week; vain keuhkosairauden
pahenemisvaiheiden yhteydessä only during exacerbations of respiratory disease
jos ei kysymykseen 91, vastaa myös kysymykseen 92 If you answered NO to question 91,
please answer question 92:
92.Oletko aiemmin käyttänyt kortisonivalmistetta tablettimuodossa? Have you previously
used oral corticosteroids? ei no; kyllä yes
vastaa kysymykseen 93 vain jos vastasit kyllä kysymykseen 92 If you answered YES to
question 92, please answer question 93:
93. Miksi lopetit kortisonitablettien käytön? Why did you stop? aloitin hengitettävän
kortisonin started with inhaled steroids; sairaus lievittyi improved; muu syy other
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reasons; käytin vain keuhkosairauden pahenemisvaiheen yhteydessä used only during
exacerbations of the respiratory disease
Yskänlääkkeet ja limaairroittavat lääkkeet  Antitussive or expectorative medicine
94. Käytätkö tai oletko aiemmin käyttänyt limaa irroittavaa tai yskänlääkettä enemmän
kuin vain tilapäisesti flunssien aikana? Do you currently use or have you earlier used
expectorative or antitussive medicines more often than rarely during common colds?
ei no; kyllä yes
vastaa kysymykseen 95 ja 96 vain jos vastasit kyllä kysymykseen 94 If you answered
YES to question 94, please answer questions 95 and 96:
95. N-asetyylikysteiini valmistetta? N-Acetylcysteine? ei no; kyllä yes
96. Muuta limaairroittavaa tai yskänlääkettä? Other expectorative or antitussive
medicines? ei no; kyllä yes
Lääkkeet nuhaoireisiin, nenäntukkoisuuteen ja silmäoireisiin Medicines for rhinitis
or conjunctivitis
97. Käytätkö tai oletko aiemmin käyttänyt pitkäaikaisesti tai toistuvasti lääkettä nuhaan tai
silmätulehdukseen? Do you currently use or have you earlier used medicines for
rhinitis or conjunctivitis?ei no; kyllä yes
vastaa kysymyksiin 98-100 vain jos vastasit kyllä kysymykseen 97 If you answered YES
to question 97, please answer questions 98-100:
98. Antihistamiini tablettimuodossa? Peroral antihistamines? ei no; kyllä yes
99. Kortisoninenäsuihketta? ei, kyllä (Nasal corticosteroids? no; yes)
100. Muuta nenä- ja silmäoireiden lääkehoitoa (esim. kromoglykaatti) Other medications
for the nose or the eyes (e.g. chromoglycate)? ei no; kyllä yes
Terveyspalveluiden tarve  Need for health care services
101. Onko Sinulla ylipäänsä mitään hengitysongelmia tai yskävaivoja tai
limannousuongelmia? Have you at all had any breathing problems or problems with
cough or phlegm? ei no; kyllä yes
102. Oletko koskaan joutunut hakeutumaan lääkärille tai muuhun hoitoon
hengenahdistuksen tai hengityksen vinkunan vuoksi? Have you ever consulted a
physician or other medical care because of breathlessness, shortness of breath, or
wheezing in your chest? ei no; kyllä yes
103. Oletko koskaan joutunut hakeutumaan lääkärille tai muuhun hoitoon pitkäaikaisen
yskän tai limannousun vuoksi? Have you ever consulted a physician or other medical
care because of long-standing cough or phlegm in your chest? ei no; kyllä yes
vastaa kysymyksiin 104-115 jos vastasit kyllä yhteenkin kysymykseen 101-103 If you
answered YES to question 101, 102, or 103, please answer questions 104-115:
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104. Oletko joutunut hakeutumaan lääkärille hengitysoireiden, yskän tai limannousun
vuoksi viimeisten 12kk aikana? Have you consulted a physician because of breathing
problems or cough or phlegm during the last 12 months? ei no; kyllä yes
vastaa kysymykseen 105 jos vastasit kyllä kysymykseen 104 If you answered YES to
question 104, please answer question 105:
105. Kuinka monta kertaa olet joutunut hakeutumaan lääkärille hengitys-, yskä tai
limannousuongelmien vuoksi viimeisten 12kk aikana? How many times have you
consulted a physician for breathing problems or cough or phlegm during the last 12
months?____
106. Käytkö säännöllisesti lääkärillä hengitysongelmien vuoksi? Do you regularly see a
physician because of your breathing problems? ei no; kyllä yes
107. Oletko hengitysvaivojen tai yskä- ja limannousuongelmien vuoksi käynyt
keuhkolääkärillä tai allergologian erikoislääkärillä? Have you consulted a specialist
in lung medicine or allergology because of your breathing problems or cough or
phlegm? ei no; kyllä yes
vastaa kysymykseen 108 vain jos vastasit kyllä kysymykseen 107 If you answered YES to
question 107, please answer question 108:
108. Onko allergian selvittämiseksi tehty ihopistokoe? (= ns. PRICK-testi) Was a skin test
performed (= so-called skin-prick test)? ei no; kyllä yes
vastaa kysymykseen 109 vain jos vastasit kyllä kysymykseen 108 If you answered YES to
question 108, please answer question 109:
109. Löytyikö PRICK-testissä allergisuutta? Was the skin-prick test positive? ei no; kyllä
yes
110. Oletko koskaan joutunut päivystysluonteisesti hoitoon hengitysvaivojen vuoksi?
Have you ever been to an emergency ward because of breathing troubles? ei no;
kyllä yes
111. Oletko ollut sairaalahoidossa hengitysongelmien vuoksi? Have you been treated as
an inpatient in a hospital because of breathing problems? ei no; kyllä yes
112. Oletko tyytyväinen lääkäripalvelujen saatavuuteen kun olet tarvinnut apua
hengitysvaivoihisi? Were you satisfied with the availability of medical care when
needed for your breathing problems? ei no; kyllä yes; en ole tarvinnut not applicable
113. Koetko, että hengenahdistus tai hengästyneisyys tai hengityksen vinkuna häiritsee
päivittäistä elämääsi? In your experience, does breathlessness or shortness of breath
or wheezing affect your daily life? ei no; silloin tällöin now and then; usein often
114. Koetko että yskä tai limannousu häiritsevät päivittäistä elämääsi? In your experience,
does  cough or phlegm affect your daily life? ei no; silloin tällöin now and then; usein
often
115. Kuinka paljon mielestäsi hengitysoireesi haittaavat jokapäiväistä elämääsi? In your
opinion, how much do your respiratory symptoms affect your daily life? ei lainkaan
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not at all; vähäisesti slightly; ajoittain kohtalaisen runsaasti sometimes moderately;
kohtalaisen runsaasti moderately; runsaasti severely
Muut kuin ahtauttavat keuhkosairaudet Lung diseases other than obstructive lung
diseases
116. Onko Sinulla muuta keuhko- tai hengityselinsairautta kuin astma, krooninen
bronkiitti tai emfyseema? Do you have or have you had any other lung or airway
disease other than asthma, chronic bronchitis, or emphysema? ei no; kyllä yes
vastaa kysymykseen 117 vain jos vastasit kyllä kysymykseen 116 If you answered YES to
question 116, please answer question 117:
117. Mitä muuta sairautta? Specify:___
118. Onko Sinulla ollut tuberkuloosi (TBC)? Have you had tuberculosis (TB)? ei no; kyllä
keuhkotbc yes, lung tuberculosis; kyllä, muu tbc yes, other tuberculosis
119. Onko Sinulla tai onko Sinulla ollut heinänuhaa tai allergista nuhaa tai
silmätulehdusta? Do you have or have you had hay fever or allergic rhinitis or
conjunctivitis? ei no;kyllä yes
120. Vaivaako Sinua usein tukkoinen tai vuotava nenä? Are you often bothered by a stuffy
or runny nose? ei no; kyllä yes
121. Onko Sinulla tai onko ollut nenäpolyyppeja? Do you have or have you had nose
polyps? ei no; kyllä yes
122. Onko Sinulla tai onko ollut (edes lapsuudessa) pitkäaikaista ihottumaa? Do you have
or have you had (even as a child) eczema? ei no; kyllä yes
123. Onko Sinulla tai onko ollut mitään tässä mainittua sydänvikaa tai sydänsairautta? Do
you have or have you had heart disease or heart problems? ei mitään no; angina
pectoris yes, angina; sydäninfarkti yes, heart attack; sydämen vajaatoiminta yes,
heart insufficiency; rytmihäiriöitä yes, heart dysrhythmia; muu sydänvika yes, other
cardiopathy
124. Käytätkö nykyisin sydänlääkitystä? Do you currently use cardiac medication? ei no;
yksi lääke yes, one drug; kaksi lääkettä yes, two drugs; kolme lääkettä yes, three
drugs; neljä lääkettä tai enemmän  yes, four drugs or more
125. Onko Sinulla tai onko ollut verenpainetautia? Do you have or have you had
hypertension?ei no; kyllä yes
126 Onko Sinulla nykyään käytössä verenpainelääkitystä? Do you currently use any
medication for hypertension? ei no; kyllä yes
126a. Käytätkö ?-salpaajalääkettä? Do you currently use ?-blocker medication? ei  no;
kyllä yes
127. Onko Sinulla jotain muuta kroonista sairautta, jota ei ole edellä mainittu? Do you
have any other disease not already mentioned?ei no; kyllä yes
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127a. Käytätkö sen vuoksi lääkitystä? Do you use regular medication for this condition?
ei no; kyllä yes (vastaa tähän jos vastasit kyllä  kysymykseen 127 answer this
question only if you answered YES to  question 127 )
Lapsuusaika Childhood
128. Tupakoiko jompikumpi vanhemmistasi tai joku samassa taloudessa asuvista kotonasi
lapsuutesi aikana? Did either of your parents or someone in your home or close
environment smoke while you were growing up? ei no; äiti mother; isä father; muu
other person
129. Oliko teillä kotona tai lähiympäristössä karvaisia lemmikkieläimiä kun olit alle
viiden vuoden ikäinen? Did you have furred animals in your home or close
environment before you were five years old? ei no; kyllä yes
130. Onko Sinulla ollut jokin vakava hengitystieinfektio kun olit alle viiden vuoden
ikäinen, esim. hinkuyskä tai keuhkokuume tai kurkunpääntulehdus? Have you had
any severe respiratory infection before the age of five years, e.g. whooping cough,
pneumonia, or croup? ei no; kyllä yes; en tiedä don’t know
131. Nukuitko yleensä samassa makuuhuoneessa muiden lasten kanssa alle viiden vuoden
ikäisenä? Did you regularly share your bedroom with any other children before the
age of five years? ei no; kyllä yes; en tiedä don’t know
132. Kuinka monta sisarusta Sinulla on/oli? How many sisters or brothers do you have or
did you have?____
133. Kuinka monta vanhempaa sisarusta Sinulla on/oli? How many older sisters or
brothers do you have or did you have?___
134. Olitko päivähoidossa leikkikoulussa tai lastentarhassa muiden lasten kanssa kun olit
alle viiden vuoden ikäinen? Did you go to a playschool or nursery with older children
before the age of five years? ei  no; kyllä yes; en tiedä don’t know
135. Asuitko viiden ensimmäisen ikävuotesi aikana? During your first five years of life,
where did you live? kerrostalohuoneistossa apartment; omakoti-, rivi tai paritalossa
house
136. Missä asuit viiden ensimmäisen elinvuotesi aikana? During your first five years of
life, did you live in the ? maaseudulla countryside; taajamassa suburb; kaupungissa
town/city
Ammatti/työ Occupation/work
137. Mikä on nykyinen työtilanteesi? What is your current working status? a) opiskelijana
studying; b) työssä working; c) työnhakijana job-seeker; d) varhaiseläkkeellä early
retirement pension; e) sairauseläkkeellä disability pension; f) vanhuuseläkkeellä
retirement pension/old age pension; g) määräaikaiseläkkeellä/sairauspäivärahalla
(>6kk) temporary sick leave (>6 months); h) kotityössä housewife/-husband; i) muu
other; j) asepalveluksessa military service; k) ei tietoa no information; l)
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työttömyyseläkkeellä unemployment pension; m) osa-aikaeläkkeellä part-time
pension
138. Mikä on nykyinen tai viimeisin työsi? Which is your current or last profession?___
NYK, SEI
139. Onko Sinulla ollut muuta työtä, joka on kestänyt yli viisi vuotta? Have you had any
other profession lasting more than five years? ei no; kyllä yes
vastaa kysymykseen 140 vain jos vastasit kyllä kysymykseen 139 If you answered YES to
question 139, please answer question 140:
140. Mikä työ/Mitä töitä? What profession(s)?___ NYK SEI
141. Kuinka monta vuotta olet asunut nykyisessä asuinkunnassasi? How many years have
you been living in your current municipality? ___ vuotta years
142. Kuinka monta vuotta olet asunut nykyisessä asunnossasi? How many years have you
been living in your current place of residence?___ vuotta years
Tupakan käyttö Smoking and nicotine use
143. Oletko Are you a … ei-koskaan polttanut never-smoker; ei-tupakoitsija nonsmoker;
entinen tupakoitsija ex-smoker; nykyinen tupakoitsija current smoker
144. Oletko koskaan tupakoinut yhtä vuotta? Have you ever smoked for one year? ei no;
kyllä yes
 (keskimäärin vähintään yksi savuke päivässä tai ainakin yksi sikari viikossa tai
vähintään 30 grammaa piipputupakkaa  kuukaudessa – yhteensä yhden vuoden ajan
on average, one or more cigarettes a day or one or more cigars a week or 30 gr or
more of tobacco a month  for one year)
145. Kuinka vanha olit kun aloit tupakoida? How old were you when you started to
smoke? ___ vuotias years
146. Altistutko tai oletko altistunut tupakansavulle kotiympäristössäsi? Are you or have
you been exposed to tobacco smoke in your home environment? ei no; kyllä,
aiemmin, ei enää yes, earlier, not now; kyllä, vieläkin yes, even now
147. Altistutko tai oletko altistunut tupakansavulle työympäristössäsi? Are you or have
you been exposed to tobacco smoke in your working environment? ei no; kyllä,
aiemmin, ei enää yes, earlier, not now; kyllä, vieläkin yes, even now
148. Altistutko yleensä toisten ihmisten tupakoinnille? Are you often exposed to tobacco
smoking of other people? ei no; kyllä yes
149. Oliko äitisi tupakoitsija raskausaikana kun hän odotti Sinua? Was your mother a
smoker when she was pregnant with you? ei no; kyllä yes; en tiedä don’t know
150.  Polttiko äitisi säännöllisesti Sinun varhaisen lapsuutesi aikana? Did your mother
smoke regularly during your early childhood? ei no; kyllä yes; en tiedä don’t know
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151. Polttiko isäsi säännöllisesti Sinun varhaisen lapsuutesi aikana? Did your father smoke
regularly during your early childhood? ei no; kyllä yes; en tiedä don’t know
Entiset tupakoitsijat Previous smokers
152. Kuinka vanha olit kun lopetit tupakoinnin? How old were you when you stopped
smoking? ___ vuotias years
153. Kuinka monta tupakkaa poltit keskimäärin päivässä ennen kuin lopetit? How many
cigarettes per day did you smoke on average before you stopped smoking? en yhtään
none; 1-4; 5-14; 15-24; ?25
154. Kuinka paljon piipputupakkaa poltit keskimäärin viikossa ennen kuin lopetit? How
much pipe tobacco per week did you smoke on average before you stopped smoking?
en yhtään none; <50 g; 50-100 g; >100 g
Nykyiset tupakoitsijat Current smokers
155. Kuinka monta savuketta poltat keskimäärin päivässä? How many cigarettes do you
smoke on average per day? en polta don’t smoke; 0-4; 5-14; 15-24; ?25
156. Kuinka monta savuketta olet polttanut keskimäärin päivässä siitä alkaen kun aloitit
tupakoinnin? How many cigarettes per day have you smoked on average since you
started smoking?en polta don’t smoke; 0-4; 5-14; 15-24; ?25
157. Jos poltat sikareja, kuinka monta poltat nykyisin keskimäärin päivässä? If you are a
cigar-smoker, how many do you smoke on average per day? en polta don’t smoke; 0-
1; 2-4; ?5
158. Kuinka monta sikaria olet polttanut keskimäärin päivässä siitä lähtien kun aloitit?
How many cigars per day have you smoked on average since you started smoking? en
polta don’t smoke; 0-1; 2-4; ?5
159. Kuinka paljon piipputupakkaa olet käyttänyt keskimäärin viikossa siitä alkaen kun
aloitit? If you use pipe tobacco, how much do you use on average per week? en käytä
don’t use; <50 g; 50-100 g; >100 g
160. Kuinka paljon piipputupakkaa olet käyttänyt keskimäärin viikossa siitä alkaen kun
aloitit? How much pipe tobacco per week have you used on average since you started
smoking? en käytä don’t use; <50 g; 50-100 g; >100 g
161. Oletko yrittänyt lopettaa tupakointia? Have you tried to quit smoking? ei no; kyllä
yes
162. Oletko ollut välillä polttamatta? Have you had any smoke-free periods? ei, tai
yhteensä alle 1 vuoden ajan no, or altogether for less than 1 year; kyllä yes, yhteensä
altogether for ____ vuotta years
